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In 2013, the Tobacco Policy Review Group published Tobacco Free Ireland, a report which set a target 
for Ireland to reduce smoking prevalence to less than 5% by 2025. The report identified tobacco-
related harm reduction as a key issue for consideration. Since e-cigarettes’ launch in the European 
Union (EU) in 2006 and in the United States of America (USA) in 2007, research on their potential 
benefits in terms of tobacco-related harm reduction, and on the public health harms of e-cigarettes, 
has grown. This systematic evidence review outlines what is known to date about using e-cigarette 
and initiation smoking tobacco cigarettes.  
Research question 
The Department of Health’s research question is ‘Does e-cigarette use by adolescents who are 
cigarette-naive at baseline lead to subsequent cigarette smoking?’  
Methods 
The research presents a systematic review of longitudinal cohort studies that examined whether e-
cigarette use leads to subsequent smoking in adolescents who are cigarette naive at baseline. The 
search covered peer reviewed literature published between 1 January 2005 and 2 October 2019 on e-
cigarettes retrieved from one of seven databases and these were Ovid MEDLINE, Cochrane Library, 
Ovid PsycINFO, Elsevier Embase, PROSPERO, LILACS, Google Scholar, and CORE.ac.uk. Comprehensive 
searches were completed and updated twice during the review period. There were three rounds of 
screening, using predefined exclusion criteria, to identify the papers included in this review. The data 
were extracted from the 21 included papers into the Cochrane Data Extraction Form. The quality of 
the included studies was assessed using the National Heart, Lung, and Blood Institute’s quality 
assessment tool for observational cohort and cross-sectional studies. The results were described 
narratively using their summary statistics in the context of their association with the exposure (e-
cigarettes), controlling for confounding using covariates. A meta-analysis feasibility assessment was 
completed in order to decide whether to complete meta-analysis and to decide which meta-analysis 
method would be most appropriate. A pairwise meta-analysis, to compare outcomes of two-armed 
longitudinal studies exposures, was completed for the smoking initiation outcomes using the primary 
studies crude and adjusted odds ratios. Sensitivity and subgroup analyses were also conducted where 
appropriate. A level of evidence and a GRADE recommendation were assigned to our findings. 
Findings 
We identified 21 papers for inclusion in the study that comprised 14 unique longitudinal cohort 
studies. The data were collected between 2013 and 2016 and the longitudinal follow-up period 
ranged from 4 months to 2.5 years. Only one study had two follow-up time points. Fifteen studies 
were completed in America and six studies were done in Europe. A variety of questions were asked 
about e-cigarettes: 17 asked about ever use of e-cigarettes, 4 asked about e-cigarette use in the past 
30 days, 4 studies asked about infrequent use of e-cigarettes, and 2 studies examined the use of both 
nicotine and non-nicotine e-cigarettes. None of the 21 studies provided any specific information 
about the e-cigarettes type, generation, or liquid. All papers measured cigarette smoking as an 
outcome variable: 18 papers investigated ever use of cigarettes by follow-up, 4 also asked about past 
30-day use of cigarettes, and 5 examined differences between groups in terms of frequency of 
cigarette use. All publications which conducted regression analysis included potential confounding 
variables as covariates in their regression model, ranging from the inclusion of 3 to the inclusion of 
17. Based on research guidance, we grouped the covariates into three groups: demographic (e.g. 
ethnicity, family affluence), interpersonal (e.g. number of friends/family members that smoke) or 
intrapersonal (e.g. such impulsivity, sensation seeking, rebellion). One paper only included variables 





variables from all three domains. The age of the included population was between 13 and 19 years at 
baseline. 
The most commonly explored association among the 21 included papers was between ever e-
cigarette use and subsequent use of cigarettes. All studies which explored this relationship, other 
than Wills et al found that there was a significant positive association between ever using an e-
cigarette at baseline and ever using a cigarette at follow-up. Our meta-analysis, which included 9 of 
the 14 unique studies, found that the combined odds of trying smoking were 4.06 (95%CI: 3.00-5.48) 
times higher for those who had ever used e-cigarettes at baseline, although this was reduced slightly 
(to 3.71 times the combined odds, 95%CI: 2.83-4. 86) when only the high-quality studies were 
included. The main meta-analysis indicated that the model had a moderate to high statistical 
heterogeneity; however, a sensitivity analysis of only high-quality studies had low to moderate 
statistical heterogeneity with a slightly reduced combined odds ratio (OR). Using the formula 
proposed by Zhang and Yu (1998), an approximation of an adjusted relative risk (risk ratio) was 
calculated for the four high-quality studies. This resulted in a range of values for the population 
attributable fraction, indicating that between 12% and 29% of those in the four studies who had tried 
a cigarette had done so due to their initial use of e-cigarettes. In other words, if e-cigarettes did not 
exist, there would have been between 12% and 29% fewer new adolescent smokers among the study 
subjects. However, it must be noted that there are limitations to this method, in particular, the fact 
that the incidence rate used in the calculation is not adjusted, and as such, these results should be 
interpreted with caution. Subgroup analyses of these studies revealed a higher combined OR for the 
data collected after 2014, a time point at which e-cigarette use increased substantially, as well as for 
the data collected in Europe (as compared with the USA). 
Four studies which examined the relationship between past-30-day e-cigarette use and initiation of 
cigarette use using the primary studies adjusted OR also found a significant positive association, 
although with a lower combined OR than ever trying e-cigarettes; indeed, a meta-analysis of three of 
these studies found that e-cigarette users had 2.14 times (95%CI: 1.75-2.62) the odds of cigarette 
smoking compared with non-e-cigarette users. Three studies measured the association between ever 
e-cigarette use and past-30-day cigarette use, with significant positive associations in the USA 
samples but no association in a Mexican sample. Neither study which measured past-30-day use of e-
cigarettes and subsequent past-30-day cigarette use found a significant association. 
Different patterns of use and frequency of use of both e-cigarettes and cigarettes reported significant 
positive associations. One USA study found significant positive associations between e-cigarettes and 
‘experimenters’, infrequent and frequent users of cigarettes. Two USA studies examined different 
frequencies of e-cigarette use at baseline on ever cigarette use at follow-up and found significant 
positive associations between all variations of e-cigarette use and subsequent smoking. Two studies 
which examined the relationship between e-cigarette use and daily cigarette use found a significant 
positive association, although this relationship was non-significant when non-nicotine e-cigarettes 
were examined. 
Two studies explored the specific impact of nicotine versus non-nicotine e-cigarettes on subsequent 
conventional cigarette use. One study which measured ever e-cigarette use and ever smoking found a 
significant positive association between ever use of e-cigarettes with nicotine and subsequent 
cigarette use, and between ever use of e-cigarettes without nicotine and subsequent cigarette use, 
although to a lesser extent. However, a study which explored the impact of nicotine versus non-
nicotine e-cigarettes on daily smoking found a significant positive association with nicotine e-
cigarettes, but no association between non-nicotine e-cigarettes and daily smoking. 
We assigned a level of evidence of 3 using British Medical Journal guidelines, as this is a systematic 
review of cohort studies, some of which had high loss to follow-up and/or very small sample sizes. 
However, with respect to certainty of evidence, the HRB authors have moderate confidence that the 
true effect is probably close to the estimated effect for trying smoking at follow-up for those who had 
ever used e-cigarettes at baseline. This is due to the fact that all analyses indicate that there is a 





and this effect size is quite large. Six studies controlled for confounding under three domains 
(demographic, interpersonal, and intrapersonal) associated with smoking cigarettes, and had a 
similar, but tighter, significant estimate of effect. The four high-quality studies also had a similar and 
tighter estimate of effect and lower statistical heterogeneity. The remainder of the studies were 
judged to be moderate quality because of their small sample sizes and loss to follow-up. In addition, 
the direction of the findings of the HRB meta-analysis are consistent with two earlier meta-analyses 
by Soneji et al. and Aladeokin et al. 
Conclusions 
We found a four-fold association between ever using e-cigarettes and initiating smoking tobacco 
cigarettes in adolescents in a combined analysis of nine cohort studies conducted with follow-up 
periods between 4 and 24 months. Sensitivity and subgroup analysis support the association between 
ever using e-cigarettes and initiating smoking tobacco cigarettes. The study design used to assess the 
relationship between e-cigarette use and initiation of cigarette smoking does not allow us to say there 
is a definitive causal relationship, but it does allow us to say that the findings builds a case towards a 
causal relationship as the findings are consistent across all studies included in the meta-analysis. 
Furthermore, the strength of association is statistically significant across all primary research studies 
in the meta-analysis. In addition, the use of e-cigarettes occurred before initiation of smoking, 
fulfilling the criteria for a temporal relationship, and two studies have examined the dose response 
relationship. Moreover, the results of this systematic review are in line with the previous systematic 
reviews and meta-analyses. Whether there are other additional explanatory factors or not, we need 
to understand what drives the relationship between e-cigarette and tobacco cigarette use and if the 
effect is definitively causal. One author recommends large longitudinal epidemiological studies which 
measure smoking onset, control for confounders, and include a propensity score measure of liability 
to smoking. Other authors suggest exploring the association using qualitative research approaches.  
We identified three theories that attempt to explain the move from e-cigarette use to smoking 
tobacco cigarettes, and these are: the gateway theory, the common liability theory, and the catalyst 
model. The gateway theory was developed to explain the observed phenomenon of young people’s 
use of alcohol and drugs in specific stages and sequences, and intimates that e-cigarette use leads to 
conventional cigarette use. The common liability theory states that there is an underlying common 
liability within people which increases their propensity to use drugs and other illicit substances, and 
that the move from e-cigarettes to conventional cigarettes or other drugs is part of their risk 
behaviours. Recently, however, some authors have proposed that the gateway theory and the 
common liability theory are not, as some say, opposing, but rather are complementary. They state 
that use of drugs in general will be explained by common factors, whereas specific factors will explain 
why young people use drugs in a specific sequence. In a 2016 paper, two authors proposed an 
alternative model, the catalyst model, to explain the path from e-cigarette use to conventional 
cigarette use, considering numerous hypotheses and pathways. They separate the process into two 
stages, from no consumption to e-cigarette consumption, and then from e-cigarette use to 
conventional cigarette use. Factors such as flavour, health, price, role model, concealment, and 
acceptance play a role in the first stage by easing the process of initiation, as they appear healthier 
and more acceptable to some, while the flavours attract others. In the second stage (i.e. the 
transition from e-cigarettes to cigarettes), the authors hypothesise that addiction, accessibility, and 
experience may drive the subsequent move to conventional cigarette use. Two factors which exist 
outside the model but are nevertheless influential are the common liability hypothesis and the 
renormalisation [of smoking] hypothesis. Despite fierce debates on the merits of different theories, 
no consensus has been reached on the most likely explanation. Future research should focus on 
designing studies which specifically set out to test these theories (or elements thereof). It would be 
beneficial for future research to attempt to isolate and unpick elements of Schneider and Diehl’s 
Catalyst model that describes e-cigarette initiation and subsequent cigarette use in order to further 
our understanding of this relationship.  
The EU has developed regulations to address e-cigarette manufacture, presentation, and sales under 
the Tobacco Products Directive (2014/40/EU). Ireland are in the process of implementing the 





address tobacco, alcohol and psychoactive drug issues, may need to be extended to tackle use of e-
cigarettes; a population health approach to psychoactive substances usually involves addressing price, 







1.1 Policy background 
In 2013, the Tobacco Policy Review Group published the report Tobacco Free Ireland, which set a 
target for Ireland to reduce smoking prevalence to less than 5% by 2025.3 Tobacco Free Ireland was 
the first policy document to be launched under the Healthy Ireland framework, and it was endorsed 
by the Government. Achieving the target in the reduction of smoking prevalence would play a major 
role in realising the vision set out in Healthy Ireland.  
The Tobacco Free Ireland report identified tobacco-related harm reduction as a key issue for 
consideration.3 It specifically highlighted the role of electronic cigarettes (e-cigarettes) as a potential 
harm reduction strategy. Since the introduction of e-cigarettes in 2006, research has expanded on 
their potential benefits in terms of tobacco-related harm reduction and on the public health harms of 
e-cigarettes. 
The Department of Health asked the Health Research Board (HRB) to complete a programme of 
research and answer five research questions: 
1. What are the public health benefits and harms of e-cigarettes? 
2. What are the public health benefits and harms of heat-not-burn products? 
3. What is the efficacy of e-cigarettes in helping people who smoke to achieve abstinence (smoking 
cessation)? 
4. Examine the efficacy of heat-not-burn products in helping people who smoke to achieve 
abstinence (smoking cessation)? 
5. Does e-cigarette use by adolescents who are cigarette naive at baseline lead to subsequent 
cigarette smoking? 
1.2 Research question 
We answered Question 5 in this review: 
Does e-cigarette use by adolescents who are cigarette-naive at baseline lead to subsequent cigarette 
smoking? 
1.3 Background 
1.3.1 Prevalence of cigarette smoking in Ireland 
The Healthy Ireland Survey 2019 reported that 17% of respondents aged 15 years and older were 
current cigarette smokers and 14% smoked daily.4 A study carried out by the European School Survey 
Project on Alcohol and Other Drugs (ESPAD) found that in Ireland 32.3% of second-level students aged 
15–16 years reported ever using a cigarette, while 13% had smoked at least once in the last 30 days.5 
Just under 7% of respondents in the ESPAD survey reported smoking daily, and of students who had 
ever smoked a cigarette, almost one-half reported that they were 13–14 years old when they first 
smoked.5  
1.3.2 Prevalence of e-cigarette use in Ireland 
The Healthy Ireland Survey 2018 reported that 92% of smokers were aware of e-cigarettes.6 The 
Healthy Ireland Survey 2019 reported that 5% of the population were using e-cigarettes, and a further 
12% had tried them at some point in the past. Furthermore, 10% of current smokers were using e-
cigarettes, 13% of ex-smokers were using them, and 1% of never smokers were using them.4 The 
Prevalence of Drug Use and Gambling in Ireland and Drug Use in Northern Ireland survey carried out 
in 2014-2015 reported that in the Republic of Ireland, 13.6% of respondents aged 15 or older had 
ever used e-cigarettes and 3.1% had used them in the month prior to the survey.7 The same survey 





reported among respondents aged 25–34 years (21.5%) and the lowest use being reported among 
those aged 65 years or older (4.6%).7 Among respondents aged 15–24 years, 14.7% had ever used e-
cigarettes. The 2016 Irish ESPAD survey reported that 23% of second-level students aged 15–16 years 
reported ever using an e-cigarette, and 10.1% reported using an e-cigarette in the 30 days prior to the 
survey.5 Slightly more than half (52.7%) of respondents who were e-cigarette users reported that they 
were 15 years old when they first used an e-cigarette. The sixth Health Behaviour in School-aged 
Children study, completed in 2018, found that the proportion of children who had ever used an e-
cigarette increased with age, from 11.5% of 13-year olds to 30% of 17-year olds. The same trend was 
noted for ever use of an e-cigarette in the month prior to the survey but the proportions were lower, 
with 4.8% of 13-year olds and 10.6% of 17-year olds reporting e-cigarette use. 8 
1.3.3 Prevalence of e-cigarette use internationally 
A study based on Eurobarometer surveys reported that 63 million people living in European Union 
(EU) member states aged 15 or older had ever used e-cigarettes by 2017 (95% confidence interval 
[CI]: 59.9 million–66.2 million), and 7.6 million (95% CI: 6.5 million–8.9 million) were regular e-
cigarette users.9 Among participants who had ever used e-cigarettes, those aged 15–24 years were 
less likely to be regular users than those aged 55 years or older (16.9% versus 38.1%). In addition, 
never smokers were less likely to be regular e-cigarette users than current and former smokers 
(12.8% versus 27.0% versus 41.3%). The proportion of people aged 15 years or older who were 
regular e-cigarette users in 2017 ranged from 4.7% in the UK to 0.2% in Bulgaria.  
A study examining data from a representative cross‐sectional survey of EU citizens found that 31.1% 
(95% CI: 30.0–32.2%) of current smokers reported ever having used e-cigarettes, 10.8% (95% CI: = 
10.0–11.7%) of former smokers reported ever having used them, and 2.3% (95% CI: 2.1–2.6%) of 
never smokers reported ever having used them. Past experimentation (7.2% [95% CI: 6.9–7.5%]) was 
more common than both current use (1.8% [95% CI: 1.6–1.9%]) and past use (2.6% [95% CI: 2.4–
2.8%]). The authors extrapolated these findings to the whole population, estimating that 
approximately 48.5 million EU citizens were ever e-cigarette users, with 76.8% of them using nicotine-
containing e-cigarettes.10 
Bauld et al. reported e-cigarette use among 60,000 people aged 11–16 years across the UK.11 Their 
data were derived from several large surveys that were completed between 2015 and 2017– the 
Youth Tobacco Policy Survey; the School Health Research Network survey based in Wales; two Action 
on Smoking and Health Smokefree Great Britain Youth Surveys; and the Scottish Schools Adolescent 
Lifestyle and Substance Use Survey – with different designs and sampling strategies. When examining 
the compiled results, Bauld et al. found that between 7% and 18% of 11–16-year-old children had 
ever used e-cigarettes. They also found that between 67% and 92% of 11–16-year-old regular 
smokers in the UK had ever used e-cigarettes in 2015–2016, while between 7% and 38% of regular 
smokers had used them once per week in the same time period. The surveys’ range for ever use of e-
cigarettes among 11–16-year-olds who regularly smoked conventional cigarettes (i.e. dual users) was 
between 4% and 10% in 2015–2016, while the range for regular e-cigarette use among the same 
cohort was between 0.1% and 0.5%. 
In the USA, data from the 2011-2018 National Youth Tobacco Surveys (Figure 1) found that current e-
cigarette use among high school students increased from 1.5% in 2011 to 20.8% in 2018.12 In addition, 
current e-cigarette use among middle school students in the USA increased from 0.6% (60,000 






Source: Cullen et al., 201812 
Figure 1 Data from the 2011–2018 National Youth Tobacco Surveys in the USA 
1.3.4 Reasons for e-cigarette use 
The 2017 Eurobarometer reported that most e-cigarette users in the EU initiated use in order to try to 
curb their tobacco intake; however, this was effective only for a minority of users.13 Specifically, of the 
15% of EU citizens who had ever used e-cigarettes, 61% of EU respondents and 58% of Irish 
respondents who started using e-cigarettes did so in order to reduce or stop their tobacco intake. Just 
14% of EU and 23% of Irish e-cigarette users stated that they stopped smoking tobacco entirely due to 
taking up e-cigarette usage, whereas 10% of EU respondents and 15% of Irish respondents said that 
they stopped smoking tobacco but then started again. Furthermore, 17% of EU respondents and 20% 
of Irish respondents said that they reduced their tobacco intake but did not stop smoking.13 
The Healthy Ireland Survey 2018 reported that 44% of 7,500 respondents who had smoked in the 12 
months prior to the survey had tried to quit during that period.6 More than one-half of current 
smokers (57%) were thinking about quitting, while 40% of current smokers had tried to quit in the 
past 12 months. Most of those who had tried to quit smoking in the past 12 months did so due to 
concerns about their health. The possible link between e-cigarette use and smoking cessation or 
reduction was not presented in the report’s findings. 
The Irish ESPAD survey reported that the most common reason for those aged 15–16 years trying e-
cigarettes was “curiosity”, at 60%, and the second most frequent answer was that “friends were using 
them”, at 21.4%.5 Fifty-one students (17.3%) reported using e-cigarettes to quit smoking tobacco and 







2.1 Conceptual methods 
A single standard systematic search approach was used for the five questions outlined in Section 1.1. 
Published studies and other material were sourced via database and supplemental searches. Articles 
were double-screened, until a final core set of relevant articles that would speak to the five review 
questions were agreed upon. For the question on smoking initiation, which dealt with peer-reviewed 
investigations (using longitudinal cohort studies), data were extracted from the material using an 
adapted Cochrane Data Extraction Form.14 
2.2 Inclusion and exclusion criteria 
The examination of the relationship between the initiation of smoking cigarettes among young people 
as a result of vaping e-cigarettes required that we included longitudinal cohort studies only, as such 
studies can measure incidence. 
For the question on smoking initiation, the date limits used are 2005-2019, as 2005 is considered the 
date of introduction of e-cigarettes as they are currently understood. 
No language limit was imposed initially (apart from the implicit limit of using databases that index 
primarily English-language research). However, on immersion in the full extent of the topic, it became 
clear that a rudimentary translation of non-English-language articles would not be adequate to 
understand such technical material and there would not be time or resources to have all the non-
English results translated professionally. Thus, reluctantly, non-English language articles were 
screened out from the articles put forward for full analysis. However, the authors are aware that a 
body of research published in other languages exists which could add to the review body of literature. 
Where duplicate articles occurred, only one of the two articles was included. Despite ‘deduplicating’ 
the articles prior to screening, some duplicates were noted at ‘title and abstract’ and at full-text 
screening stages. These are likely to have got through the deduplication process due to inaccurate or 
incomplete information in some of the search fields, for example, wrong or missing titles or authors, 
missing digital object identifiers, or other information types. 
The study inclusion criteria for ‘Does e-cigarette use lead to subsequent smoking in adolescents (who 
are cigarette naive at baseline)?’, are described in Table 1. 
Table 1 PICO inclusion criteria for review question 
Element Description 
Population Adolescents who are cigarette naive at baseline. The age of the included population was 
between 13 and 19 years or under at baseline. 
Exposure Electronic cigarette vaping at baseline or in the past 
Comparators Non-electronic cigarette user 
Outcomes Initiation of cigarette smoking at follow-up 
Study design Cohort studies 
Search dates 2005-2019 for e-cigarettes 
2.3 Information searches 
Following scoping searches on the topic of e-cigarettes and heat-not-burn products in Ovid MEDLINE 
and Ovid PsycINFO, and in the search engine Google, a search plan was designed by the information 
specialist to capture relevant studies and other data. The plan included literature searches using 
bibliographic databases, registries, repositories, and search engines. Supplemental searches were 





authoritative reports. Follow-up searches of Ovid MEDLINE were scheduled to be carried out after the 
initial main search, to maintain currency of the review. 
‘Search development’ database work was carried out from 4 to 10 April 2019 and the finalized 
searches for each database were run on the 15 April. These results were combined using EndNote X7 
and uploaded to EPPI-Reviewer 4 (V. 4.11.0.0)15 Subsequent supplemental searches were carried out 
on the 12 August and 2 October 2019 August and October 2019. 
2.3.1 Bibliographic databases 
General scoping searches were carried out in late March 2019 using Ovid MEDLINE and PsycINFO, and 
using the search engine Google, to estimate the size of the body of published information and to test 
search terms. The primary database searches were carried out on the 15 April 2019. The databases 
included were: 
• Ovid MEDLINE (Ovid MEDLINE® and Epub Ahead of Print, In-Process & Other Non-Indexed 
Citations, Daily and Versions® 1946 to April 12, 2019) 
• Elsevier Embase 
• Ovid PsycINFO 
• Wiley Cochrane Database of Systematic Reviews 
• Wiley Cochrane Central Register of Controlled Trials 
• LILACS (including the databases LILACS, IBECS, CUMED, BDENF – Nursing, BBO – Dentistry, WHO 
IRIS, PAHO IRIS, Index Psychology – Scientific journals and MedCarib) 
• PROSPERO (Centre for Reviews and Dissemination, University of York) 
Peer review of the search strategy by another information specialist, as recommended in the Peer 
Review of Electronic Search Strategies (PRESS) guidelines,16 was not carried out as resources were 
unavailable when conducting the searches. However, every effort was made by the information 
specialist to critically appraise the search strategies using the checklist outlined in the PRESS 
guidelines in order to follow the PRESS recommendations. 
On the 12 August 2019, a two-part supplemental search was carried out. This included a literature 
search using Ovid MEDLINE (with the same search terms as the original search but limited to recent 
articles), and a citation search based on core reviews and reports. The list of reports and reviews used 
for this search is included in Appendix 1. The review titles were sourced by combining the Ovid 
MEDLINE e-cigarette and heat-not-burn searches with a customised version of the Ovid Expert 
Searches systematic review filter and then limiting them to publications from the previous five years. 
The titles were screened for clinical relevance in accordance with PICO (e.g. smoking cessation, 
harms, benefits, and initiation) by the information specialist and titles were confirmed for inclusion 
with the lead reviewer. The results from these searches were added to EndNote X7 and screened 
initially for duplicates, then for relevance using the review PICO (see Table 1), and then for originality 
(whether they were already included in the original search results). 
 On 2 October 2019, a second simple supplemental search was carried out using Ovid MEDLINE, with 
the same search terms as before. The results were screened initially by the information specialist to 
eliminate articles that had already been screened in other searches, and to eliminate highly irrelevant 
articles (e.g. articles not relating to e-cigarettes or heat-not-burn devices). The results were screened 
by the researchers and any relevant articles were retained. 
The full search strategies used in the initial searches for Ovid MEDLINE and other databases are 
included in Appendix 1. The MEDLINE searches used in the supplemental searches were the same as 
the initial MEDLINE strategy. 
The searches were broadly comprehensive but not exhaustive. The use of journal hand-searching, 





for this review, but due to time considerations, it was not possible to incorporate all these methods in 
this project. 
2.3.2 Keywords 
Keywords for these searches were compiled from scoping searches on the topic carried out in 
MEDLINE and Google, and with the assistance of PubMed PubReMiner,17 the PubMed text-mining 
software. This software allowed the easy capture of relevant medical subject headings (MeSH) terms. 
The keywords used in building the searches were based on variations of terms for e-cigarette and 
heat-not-burn products, for example, e-cig*, e-liquid, vape, vaping, cigalike, HnB (heat-not-burn 
products), heatsticks, electronic nicotine delivery system (ENDS), and electronic non-nicotine delivery. 
Non-English terms for these concepts were also included, for example, e-sigaret*, E-zigarette, and e-
papieros. Some high-profile brand names such as JUUL and IQOS were included. 
For databases with a controlled vocabulary, such as MEDLINE, Cochrane, PsycINFO, PROSPERO and 
Embase, terms from the relevant thesaurus (MeSH, Emtree, PsycINFO Thesaurus) were also 
incorporated. 
Given the considerable body of literature published to date mentioning e-cigarettes and heat-not-
burn products and the limited amount of time available to complete the review, additional search 
terms were used to broadly exclude some categories of study, for example, MeSH and free terms for 
animal studies and cell line studies. 
Rather than split the single e-cigarette/heat-not-burn products search into three separate searches 
for smoking cessation, harms and benefits, and initiation studies, a single search was used for all 
three subtopics, and results were filtered via the screening process to the appropriate subtopic. It was 
anticipated that several results would be relevant to more than one question. 
2.4 Screening 
A comprehensive screening process was carried out. Results (n=6,510 after deduplication) from the 
literature searches were exported to EPPI-Reviewer 4. ‘Title and abstract’ screening was carried out 
by two researchers (AMcC and DOB) and the information specialist (CL). A pilot group consisting of 
10% of the results were initially screened to test the screening questions and process. The remainder 
of the results was then screened using the same criteria. The screening questions comprised the five 
review questions. Where there was doubt about the relevance of an article, it was included for the 
next round of screening. 
Inclusion and exclusion criteria for the title and abstract screening process were those outlined in 
Section 2.2. 
After the title and abstract stage of screening, 130 papers relating to the research question were 
retained. The full texts of the relevant 130 papers were sourced and then screened to answer specific 
inclusion queries that could not be answered using the published abstract alone. This screening was 
carried out by two of the researchers (AMcC, and DOB), using the same inclusion and exclusion 
criteria as before. 
After this extended preliminary screening, 46 papers were carried forward to the full-text screening 
process. Despite a thorough screening process, some articles had to be excluded on deep 
examination during the data extraction process, as on close reading, they did not fulfill the inclusion 
criteria of the study. In some cases, details of study type or methods were unclear. Some of the 
articles included inadequate descriptions of the analyses carried out, which required contact with the 
original authors to obtain full details. Following full-text analysis, 18 papers were included for data 
extraction. 
The results of the two supplemental searches (described in Section 2.3.1) were screened by title and 
abstract by the information specialist to eliminate obviously out of scope results. Potentially relevant 





relevant results were retrieved. These were added to the 18 papers remaining after screening and 
resulted in 21 papers eligible for data extraction. 
2.5 Data extraction 
One researcher (DOB) extracted data from the 21 included papers into the bespoke Cochrane Data 
Extraction Form14 under the following headings: ‘study identifier’, ‘general information’, ‘study 
characteristics’, ‘participants’, ‘exposure group 1’, ‘exposure group 2’, ‘outcomes’, ‘data and analysis’ 
and ‘other information’. JL validated the extraction and any disagreements were resolved by 
consensus. DOB noted during extraction that a number of the papers were based on data from the 
same datasets and so identified studies that were linked and grouped them for analysis and 
presentation. As stated above, the final total included 14 unique studies published in 21 journal 
papers. 
2.6 Quality assessment 
DOB and JL assessed the quality of the included studies using the National Heart, Lung, and Blood 
Institute’s (NHLBI’s) quality assessment tool for observational cohort and cross-sectional studies.18 
This tool uses 14 items to assess the quality of cohort studies (Appendix 2).  
Each study was independently assessed by two researchers (DOB and JL), with any disagreements 
being resolved by consensus. The results of the quality assessment are presented in Appendix 2. 
Quality assessment results were not used to exclude studies from the main analysis, but the 
assessment was used to describe the main strengths and limitations of the studies. In addition, the 
quality assessment results were used to inform our choice of high-quality studies for one of the 
sensitivity analyses.  
2.7 Data analysis 
The results were described narratively using summary statistics and describing the influence of 
covariates. They are presented according to different categories of frequency of both e-cigarette use 
at baseline and tobacco smoking at follow-up, taking account of different follow-up periods.  
Meta-analysis is the statistical pooling of two or more trials comparing the same two interventions.19 
A core assumption underpinning meta-analysis is that the studies being pooled are homogeneous; all 
sources of heterogeneity and variation must be assessed before meta-analysis can be carried out.19 20 
A feasibility analysis is an assessment of variation in study and patient characteristics across 
comparisons that affect the summary measures of effects (such as the odds ratio) for the exposure or 
interventions of interest relative to an overall reference exposure or treatment.20-22 The feasibility 
assessment was completed in order to decide whether to complete meta-analysis, as well as to 
decide which meta-analysis method would be most appropriate. The feasibility analysis considered 
outcome, exposure, unit of measurement, and length of time to follow-up (Appendix 3). Based on 
these criteria, 12 studies were considered eligible for pairwise meta-analysis so as to compare 
outcomes of two armed longitudinal studies exposures. A separate meta-analysis was done using 
both the primary studies’ crude odds ratio and their adjusted odds ratio (AOR) for ‘ever use’ of e-
cigarettes and cigarettes (n=9), and for ‘past 30-day use’ of e-cigarettes (n=3). We also completed 
sensitivity analysis and subgroup analysis on the ‘ever use’ data. We used the ‘Metagen’ package for 
the R programming language.23 24 This package uses the inverse variance method for weighting of 
studies.23 24 The I² statistic describes the percentage of the variability in treatment effects that is due 
to statistical heterogeneity rather than sampling error (chance).19 Random and fixed effects models 
were run, although the random effects model is preferred due the underlying statistical 
heterogeneity in the studies. Odds ratios and their associated 95% confidence intervals (CI) were 
calculated. Where data from the included studies were unclear, we did not include them in meta-
analysis. 
One of our sensitivity analyses explored the impact of studies which appropriately controlled for 
confounding. Based on Glasser et al., we defined the three domains of covariates (which may be 





family affluence), interpersonal (such as number of friends/family members that smoke) or 
intrapersonal (such as impulsivity or sensation seeking).25 Studies which included covariates in all 
three domains were considered well-controlled studies.  
We calculated the population attributable fraction (PAF) for the high-quality studies included in the 
main meta-analysis. The PAF is the excess risk of disease in the study population due to the presence 
of the exposure (in this case, e-cigarettes). It is used to assess the public health impact of the 
exposure (e-cigarettes) on conventional cigarette use. It is the percentage of cigarette smoking, 
among the study population that used e-cigarettes, that could be prevented if e-cigarettes were 
removed.26 In order to calculate the fraction for the included studies in this report, the following 
three steps were taken: 
1. Used four high-quality studies 
2. Converted AORs to risk ratios,27 and 
3. Calculated PAF using risk ratios.28 26 
However, it must be noted that there are limitations with the method used in this analysis,27 
particularly the fact that the incidence rate used in the calculation is not adjusted, and as such, these 
results should be interpreted with caution.29 30 
2.8 Level of evidence  
We used the British Medical Journal guidelines to assign the level of evidence,31 and the GRADE 
certainty of evidence,32 to write our strength of evidence recommendation. The levels of evidence 
range from one to four. The certainty of evidence can be high, moderate, low or of very low quality. 
The quality of evidence drives the strength of recommendation, which is one of the last translational 






3 Results  
3.1 Descriptive characteristics of included studies  
The PRISMA flow chart (Figure 2) shows the numbers of articles examined at each stage of the review 
process. From an initial 6,619 studies (6,510 papers from the initial searches, plus 109 papers from 
supplemental searches), 14 unique studies in 21 papers met the inclusion criteria for this systematic 
review. Of these papers, the majority (n=12) were from the USA, 3 were from the UK, 2 were from 
Canada, 1 was from Finland, 1 was from Germany, 1 was from Mexico, and 1 was from the 
Netherlands. As per the inclusion criteria, the age of the included population was 19 years or under at 
baseline. Most studies had one follow-up period, although one reported follow-up data at two time 
points.33 The follow-up periods ranged from 4 months to 2.5 years, with data collected between 2013 


























Figure 2 PRISMA flow chart  
 
 
Records included after title and 
abstract screening 
(Smoking initiation: N=130) 
Records included after full-text 
screening  
(N=46) 
Papers included in final analysis 
(N=21) 
Records excluded: (N=5675) 
Records assigned to other review 
questions: (N=705) 
Records excluded from smoking 
initiation set: (N=84) 
Records included from supplemental 
searches: (N=3) 
Duplicate records excluded 
(N=8,163) 
Records identified through database, search engine and repository searches 
(N=14,673) 
(Databases: MEDLINE: n=3,874; Embase: n=4,212; PsycINFO: n=1,519; 
Cochrane Central Register of Controlled Trials: n=527; Cochrane Database of 
Systematic Reviews: n=14; LILACS: n=4,042; PROSPERO: n=93) 
Records after duplicates removed 
(N=6,510) 






3.1.1 Measurement of exposure 
The exposure variable for all papers was the use of e-cigarettes at baseline, although the frequency of 
exposure differed among studies. The majority (n=17) asked about ever use of e-cigarettes at 
baseline,33-49, four studies asked about e-cigarette use in the past 30 days,50 38 51 43 two studies asked 
about any prior use of e-cigarettes38 52 and four studies asked about infrequent use of e-cigarettes 39 
52 47 48 and frequent use of e-cigarettes 39 52 47 48 Two studies examined the use of both nicotine and 
non-nicotine e-cigarettes.44 49 None of the 21 studies provided any specific information about the e-
cigarette type, generation or liquid. Apart from Treur et al.44 and Kinnunen et al.49, all other authors 
assumed that e-cigarettes contained nicotine.  
3.1.2 Measurement of outcome 
All papers measured cigarette smoking as an outcome variable. The majority (n=18) investigated ever 
use of cigarettes by follow-up; 33 34 36-48 50-52 however, some also asked about past-30-day use of 
cigarettes (n=4)37 38 41 43 or examined differences between groups in terms of frequency of cigarette 
use (for example, experimenters, infrequent smokers, or frequent smokers)  (n=5). 35 39 49 50 53  
3.1.3 Covariates 
All publications which conducted regression analysis included potential confounding variables as 
covariates in their regression model, ranging from the inclusion of 3 variables48 to the inclusion of 17 
variables.37 
Based on Glasser et al., we defined the three domains of covariates in this topic area as demographic 
(e.g. ethnicity, family affluence), interpersonal (e.g. number of friends/family members that smoke), 
and intrapersonal (e.g. impulsivity, sensation seeking).25 Although the majority included covariates 
from all three domains, there was some diversity in the number of covariates included in each study; 
one paper 35 only included variables from one domain, eight papers included variables from two 
domains34 42 44 46 47 49-51 and 10 papers included variables from all three domains. 33 37-41 43 45 48 53  
Of the 19 papers that conducted regression analysis on the association between e-cigarette use and 
conventional cigarette use, 10 studies controlled for covariates in all three main domains: 
demographic, interpersonal, and intrapersonal. 
3.1.4 Quality assessment 
Overall, using the NHLBI quality assessment tool, we determined that there was a variation in the 
quality of our included papers.18 We judged that there were four high-quality studies as they had a 
representative and clearly defined sample with a participation rate of more than 50%, a loss to follow-






Table 2 Characteristics of included studies 




















The authors examined whether baseline 
use of e-cigarettes among a Canadian 
sample of susceptible and non-susceptible 
never-smoking youth was associated with 













The authors examined e-cigarette use in a 
large longitudinal sample of Canadian 
youth, including the extent to which e-
cigarette use was associated with cigarette-
smoking initiation at 1-year follow-up.  
2013–
2015 
1 year Canada 14–18 23.0% 19,310 
Barrington-












The authors evaluated the association of 
baseline e-cigarette use (never or ever) 
with cigarette use frequency at follow-up. 
Also, to evaluate transitions between 
baseline ever or past-30-day single or dual 
product use and past-30-day single or dual 





















The authors examined the sensitivity, 
specificity, and predictive value of the 
susceptibility to smoking index in a 
prospective cohort study of non-smoking 
Southern California adolescents as they 
turned 18, the legal age for smoking at the 



































The authors examined whether e-cigarette 
use among older adolescents in the 
transition to adulthood leads to greater 
likelihood of initiation of cigarettes as they 


























The authors evaluated the associations of 
prior e-cigarette and other noncigarette 
tobacco product use with subsequent 




2 years USA 13.4 (12–15) 19.1% 6,123 




The authors simultaneously assessed e-
cigarettes, hookah, noncigarette 
combustible tobacco, and smokeless 
tobacco as determinants of future cigarette 
smoking, including whether poly use of 
noncigarette products has a greater 
association with future smoking compared 
with use of 1 product alone. 
2013–
2015 
1 year USA 14.3 (12–17) 12.1% 10,384 









This study investigated the extent to which 
baseline ever use of e-cigarettes was 
associated with the initiation or escalation 
of cigarette use (objectively validated) 12 
months later in a sample of UK adolescents 
aged 13–14 years. The impact of controlling 
for various smoking risk factors such as 
2014–
2015 























friends and family smoking and their 
moderating effects was also explored. 







This study explored the associations 
between e-cigarette use and smoking 
initiation among young people in Great 
Britain. 
2016 4–6 months 
Great 
Britain 
(11–18) 50% 2,916 




This study investigated whether 
adolescents entering the 9th grade in Los 
Angeles, California, who reported ever 
using e-cigarettes were more likely to 
initiate the use of combustible tobacco 



















Associations of vaping with subsequent 
smoking frequency and heaviness pattern 
among adolescents were examined. 
2014–
2015 











The aim of this study was to evaluate if e-
cigarette trial among Mexican youth who 
had not previously smoked cigarettes or 
used marijuana increased the likelihood of 
trial and use of conventional cigarettes or 
marijuana use at 20-month follow-up. 
2015–
2016 









This study prospectively examined vaping 
as a predictor of future cigarette smoking 
among youth with and without previous 
cigarette smoking experience. A secondary 


































The aim of this study was to evaluate 
whether e-cigarette use in adolescence can 




6 months Germany 15.61 7.3% 2,358 




The present study examined the extent to 
which e-cigarette use among never 
cigarette smokers at time 1 of the study 
was predictive of cigarette smoking status 
at time 2 (one year later), while controlling 
for other relevant variables that 
independently may predict the uptake of 
cigarettes. A secondary purpose of this 
study was to examine if several factors 
previously predictive of the onset of 
cigarette smoking (anxiety, depression, 
peer deviance, stressful life events, 
impulsivity, and the use of other tobacco 
products and marijuana) predicted the 
onset of e-cigarette use among initial never 
users of either cigarettes or e-cigarettes. 
2014–
2015 




Treur et al. 
(2018)44 
Cohort study 
The authors aimed to 1): investigate the 
prevalence and sociodemographic 
patterning of three major types of 
alternative tobacco (e-cigarettes with 
nicotine, e-cigarettes without nicotine and 
waterpipe) and 2): investigate the 
association between alternative tobacco 
2014–
2015 























and conventional smoking, cross-sectionally 
in the total sample and longitudinally in a 
subsample whereby we take adolescents’ 
propensity to smoke into account. 




The authors tested the role of cognitive and 
social factors for mediating the relation 




1 year USA 14.7 (14–16) 44.4% 1,984 




The authors tested whether the effect of e-
cigarette use for smoking onset differs for 
youth who are lower versus higher on 
propensity to smoke. 
2013–
2014 
1 year USA 14.8 44.4% 1,984 




The authors primary aim was to test 
whether e-cigarette use is related to the 
onset of smoking; thus, among adolescents 
who had never smoked at time 1 (T1), we 
determined the likelihood of smoking at 
time 2 (T2) as a function of previous e-
cigarette use. A second aim was to 




1 year USA 14.7 (14–16) 44.4% 1,984 




This study examined whether young never 
smokers in Scotland, UK who have tried an 
e-cigarette are more likely than those who 




1 year Scotland 14.4 (11–18) 29.6% 3,001 




This longitudinal study explored whether 
nicotine and non-nicotine e-cigarette uses 
predict the daily use of two different 
2014–
2016 



















nicotine products, namely conventional 
cigarettes and nicotine e-cigarettes. 






3.2.1 Ever e-cigarette use/ever cigarette use 
Fourteen papers (11 unique studies) explored the relationship between ever e-cigarette use at 
baseline and subsequent trial of cigarettes at follow-up. Most of these papers used regression models 
to produce adjusted odds ratios (AORs), including varying numbers of covariates, with all except Wills 
et al. (2016)45 finding significant associations (Table 3). 
In the USA, using data from the Children’s Health Study, Barrington-Trimis et al. (2016)34 measured 
ever use of cigarettes at a 16-month follow-up among baseline ever e-cigarette and cigarette users in 
two different models.34 Both the model which included demographic covariates only (AOR: 6.17; 95% 
CI: 3.3–11.6), and the model which also included use of alternative tobacco products as covariates 
(AOR: 5.48; 95% CI: 2.69–11.2), found a significant positive association between ever use of e-
cigarettes at baseline and initiating smoking cigarettes at follow-up.34 Berry et al. (2019), using data 
from the USA PATH Study, produced a model which adjusted for all three domains of covariates, 
finding a significant positive association between ever e-cigarette use and initiating cigarette use 
during a 2-year follow-up (AOR: 4.09; 95% CI: 2.97–5.63).37 Watkins et al. (2018) – who used the same 
cohort, although with data from a 12-month follow-up point – also found a significant positive 
association between ever e-cigarette use and initiating smoking cigarettes during follow-up (AOR: 
2.53; 95% CI: 1.8–3.56).38 Leventhal et al. (2015) explored the association at a 6-month and 12-month 
follow-up in a convenience sample based in California.33 Using a model which adjusted for variables in 
all three domains and averaged across the two time points, they found a significant positive 
association (AOR: 1.75; 95% CI: 1.1–2.77).33 Spindle et al. (2017), again using a sample population 
from the USA, also found a significant positive association between ever e-cigarette use and ever 
cigarette use (AOR: 3.37; 95% CI: 1.91–5.94). 43 One Hawaiian study, controlling for demographic and 
intrapersonal variables, also found a significant effect (AOR: 2.87; 95% CI: 2.03–4.05).47 Wills et al. 
(2017a) explored the same relationship in the same sample, this time including propensity to smoke 
as a variable, and also found a significant positive association (estimate 0.8, SE 0.18).46 
Wills et al. (2016), using the same Hawaiian sample as above, explored the mediating effect of social 
and cognitive factors on the relationship between e-cigarette use and subsequent cigarette use (Table 
3).45 Their autoregressive model showed that e-cigarette use was related to all the mediators (in 
particular marijuana use (r2 = 0.51) and smoking expectancies (r2 =0.4)) collected at the second time 
point, resulting in a non-significant direct positive effect between e-cigarette use and cigarette use, in 
a model which accounted for 34% of the variance (r2 =0.34). In order to address temporal ambiguity, 
the authors also produced a model in which data for the mediators collected at the first time point 
were considered, which found a significant direct positive association between e-cigarette use and 
subsequent smoking (r2 =0.18).45 The discrepancies in these results demonstrate that more complex, 
or sophisticated, measures of confounders (including different data collection points) can alter causal 
interpretations.54 
In the UK, Conner et al. (2018) explored associations between baseline e-cigarette use with ever 
cigarette use at a 12-month follow-up, adjusting for covariates across the three main domains.39 They 
found that there was a significant difference between those who had used e-cigarettes and those 
who had not in terms of subsequent cigarette use (AOR: 4.06; 95% CI: 2.94–5.6).39 East et al. (2018) 
also explored this relationship in the UK, although at a 4–6-month follow-up, controlling for variables 
across the three main domains, and found a significant positive association (AOR: 10.57; 95% CI: 
3.33–33.5).40 Similarly, Best et al. (2018), controlling for interpersonal and intrapersonal variables in a 
UK sample, also found a significant positive association at 1 year (AOR: 2.42; 95% CI: 1.63–3.6).48 
Two studies analysed the relationship between baseline e-cigarette use with ever cigarette use using 
adjusted risk ratio (ARR) as outputs (Table 4). Lozano et al. (2017) explored the association between 
ever e-cigarette use at baseline and initiated ever cigarette use at a 20-month follow-up in Mexico.41 
Using a model which adjusted for variables in all three main domains, they found that the risk of 
cigarette use increased for e-cigarette users (ARR: 4.4; 95% CI: 1.22–1.6). Morgenstern et al. (2018) 





follow-up in a German sample.42 Controlling for demographic and intrapersonal variables, they also 
found a significant positive association (ARR: 2.18; 95% CI: 1.68–2.83).42 
One Dutch study explored the relationship between both nicotine and non-nicotine e-cigarette use at 
baseline and subsequent use of cigarettes.44 Adjusting for demographic and intrapersonal variables, 
the authors found a significant positive association between ever use of e-cigarettes with nicotine and 
subsequent cigarette use (AOR: 11.9; 95% CI: 3.36–42.12) and for ever use of e-cigarettes without 




















Trimis et al. 
(2016)34 
Ever use Ever use 6.17* 3.3 11.6 Gender; ethnicity; grade; highest parental education Y N N 
Barrington-
Trimis et al. 
(2016)34 
Ever use Ever use 5.48* 2.69 11.2 
Gender; ethnicity; grade; highest parental education; use of 
hookah; use of cigar; use of pipe 
Y N Y 
Berry et al. 
(2019)37 
Ever use Ever use  4.09* 2.97 5.63 
Sex; age; race/ethnicity; parental education; urban or rural 
residence; living with tobacco user; noticing tobacco warnings; 
tobacco advertisement receptivity; ever alcohol use; ever 
marijuana use; prescription drug abuse; enjoying frightening 
things; liking new and exciting experiences; preferring 
unpredictable friends; willingness to smoke in next year; curiosity 
about cigarettes; susceptibility to cigarette peer pressure from 
friends 
Y Y Y 
Watkins et al. 
(2018)38 
Ever use Ever use  2.53* 1.8 3.56 
Hookah use; non-combustible cigarettes; smokeless tobacco use; 
gender; age; race/ethnicity; parental education; urban residence; 
sensation seeking; ever used alcohol; living with tobacco user; 
notice of cigarette warning labels; tobacco advertising receptivity; 
summer season 
Y Y Y 
Conner et al. 
(2018)39 
Initiation Ever use 4.06* 2.94 5.6 
Friend smokers; gender; family smokers; intention; attitudes; 
norms; perceived behavioural control; self-efficacy; free school 
meals 
Y Y Y 
East et al. 
(2018)40 
Initiation Ever use 10.57* 3.33 33.5 
Age; gender; school performance; problem behaviour; monthly 
alcohol use; smoking susceptibility; e-cigarette susceptibility; 
some friends smoke; some friends use e-cigarettes; at least one 
parent smokes; at least one parent uses e-cigarettes; sibling(s) 
smoke; sibling(s) use e-cigarettes; public approve of smoking; 
public approval of e-cigarettes 















Covariates Demographic Interpersonal 
Intraperso
nal 
East et al. 
(2018)40 
Initiation Ever use 11.89* 3.56 39.72 
Age; gender; school performance; problem behaviour; monthly 
alcohol use; smoking susceptibility; e-cigarette susceptibility; 
some friends smoke; some friends use e-cigarettes; at least one 
parent smokes; at least one parent uses e-cigarettes; sibling(s) 
smoke; sibling(s) use e-cigarettes; public approve of smoking; 
public approval of e-cigarettes; follow-up e-cigarette use 
Leventhal et 
al. (2015)33 
Ever use Ever use 1.75* 1.1 2.77 
Gender; ethnicity; living with biological parents; substance use; 
family history of smoking; age; parental education; peer smoking; 
scale for depressive symptoms; subscale for impulsivity; 
delinquent behaviour; smoking susceptibility; smoking 
expectancies; time; ever e-cigarette use by time 
Y Y Y 
Spindle et al. 
(2017)43 
Ever use Ever use 3.37* 1.91 5.94 
Gender; age; ethnicity; depression; anxiety; negative urgency; 
positive urgency; lack of premeditation; lack of perseverance; 
sensation seeking; stressful life events; peer deviance; other 
tobacco use 
Y Y Y 
Treur et al. 
(2018)44 
Ever use 
Ever use of 
nicotine e-
cigarette 
11.9* 3.36 42.11 
Sex; age; educational level; propensity to smoke; interaction Y N Y 
Treur et al. 
(2018)44 
Ever use 
Ever use of 
non-nicotine 
e-cigarette 
5.36* 2.73 10.52 
Wills et al. 
(2017b)47 
Ever use Ever use 2.87* 2.03 4.05 
Age; gender; ethnicity; parental education; parental support; 
rebelliousness 
Y N Y 
Best et al. 
(2018)48 
Ever use Ever use 5.97* 3.12 11.40 
Sex; age; family affluence scale; ethnic group; school; 
susceptibility to smoking at baseline; any family member smokes 
at baseline; at least some friends smoke at baseline; interactions 
between e-cigarettes and susceptibility; interactions between e-
cigarettes and friends smoking 
Y Y Y 

























Lozano et al. 
(2017)41 
Ever use Ever use 1.4* 1.22 1.6   
Sex; age; parents’ 
socioeconomic status (SES); 
sensation seeking; friends 
that smoke; parents that 
smoke; siblings that smoke; 
tried alcohol; binge 
drinking; Internet tobacco 
product advertising 
Y Y Y 
Morgenstern 
et al. (2018)42 
Ever use Ever use 2.18* 1.68 2.83   
Sex; age; federal state; 
school type; migration 
background; school-leaving 
qualification of parents; 







ever e-cigarettes use; ever 
alcohol use; ever binge 
drinking; ever cannabis use; 
ever other illegal drugs use 
Y N Y 
Wills et al. 
(2016)45 
Ever use Ever use    .08¥  
Smoker prototypes; 
smoking expectancies; peer 
smoker affiliations; 
marijuana score; gender; 
ethnicity; family structure; 
parental education 





Wills et al. 
(2016)45 
Ever use Ever use    0.18*  
Gender; ethnicity; family 
structure; parental 
education 
Y N N 
Wills et al. 
(2017a)46 
Initiation Ever use     
0.8 
(0.18)* 
Gender; ethnicity; father 
education; propensity to 
smoke; e-cigarette use by 
propensity 
Y N Y 







In order to ascertain whether a meta-analysis was feasible, or indeed appropriate, a feasibility 
analysis was conducted, taking outcome, exposure, unit of measurement, and length of time to 
follow-up into account as they employed the same method of analysis. Based on these criteria, nine 
studies with 16,808 participants were considered eligible for meta-analysis. Appendix 3 presents the 
full feasibility analysis. Several subgroup and sensitivity analyses were conducted to assess the 
influence of issues (such as quality, control for covariates, time to follow-up, study location and data 
collection year) raised in the feasibility assessment, as described below.  
Using the ‘Metagen’ package,23 24 we conducted a meta-analysis on studies which explored the 
association between ever use of e-cigarettes at baseline and ever use of cigarettes at follow-up, in 
cigarette-naive adolescents at baseline (Figure 3).  
 
Figure 3 Meta-analysis results, using individual study AOR, for association between ever e-cigarette 
use and subsequent smoking 
The meta-analysis displays a statistically significant positive effect on ever e-cigarette use and 
subsequent smoking (AOR: 4.06; 95% CI: 3–5.48; I2: 68%), using AORs in a random effects model, 
which estimates different, yet related, intervention effects (see Appendix 3 for a meta-analysis of 
crude or unadjusted odds ratios). A random effects analysis allows us to address statistical 
heterogeneity that cannot be readily explained by other factors.19. The I2 of 68% indicates that there 
is moderate to high statistical heterogeneity between studies. In examining the model, it is apparent 
that East et al., Treur et al. and Leventhal et al. are outliers in the group. 33 40 44 This may be explained, 
in part, by the fact that East et al. had very small numbers in the exposed group, 40 Treur et al. 
examined e-cigarettes with nicotine specifically and the number in the exposed group is unknown,44 
and Leventhal et al. used a convenience sample 33 
3.2.1.2 Sensitivity analysis 
In addition to the main analysis, two sensitivity analyses were conducted; one to assess the impact of 
the low-quality studies on the overall result, and one to assess the impact of the studies which did not 
control for the three confounder categories (demographic, intrapersonal, and interpersonal factors) 
in the regression models results.  
Four studies were deemed to be of ‘high quality’, answering ‘yes’ to at least three of the four bulleted 
questions listed below, and thus indicating a high-quality study design.37 43 47 48 A question addressing 






• Were all subjects selected or recruited from the same or similar populations (including same time 
period)? Were inclusion and exclusion criteria for being in the study prespecified and applied 
uniformly to all participants? 
• Was the participation rate of eligible persons at least 50%? 
• Was loss to follow-up 20% or less? 
• Was a sample size justification, power description, or variance and effect estimates provided? 
This final question was weighted more heavily, as any study which answered ‘no’ to this question 
was excluded from the meta-analysis subgroup. 18 
Four studies37 43 47 48 were included in the meta-analysis for high-quality studies, and the AOR was 
3.71 (95% CI: 2.83–4.86; I2 35%), which represents a reduced AOR, with narrower CIs, once the lower-
quality studies are removed. Of note, the level of statistical heterogeneity is almost halved at 35%, 
indicating low to moderate statistical heterogeneity which may be explained by representative 
sampling and adequate sample sizes. A further sensitivity analysis was conducted on the six studies33 
37 39 40 43 48 which appropriately controlled for the three domains of covariates – that is, demographic, 
interpersonal, and intrapersonal factors. The results of this analysis (AOR: 3.82; 95% CI: 2.66–5.48; I2 
69%) were very similar to the results for the high-quality studies assessment, but the level of 
heterogeneity remains moderate to high.  
3.2.1.3 Subgroup analyses 
In addition to the sensitivity analyses, three subgroup analyses were conducted. The first considered 
studies which collected data pre-201433 37 47in comparison with those which collected their initial data 
post-2014,34 39 40 43 44 48 due to the increase in e-cigarette use that was observed around this time.55 
As seen in Table 5, the AOR for studies which collected data from 2014 onwards increased 
substantially. 
Table 5 Subgroup analyses of data collected pre- and post-2014 
Subgroup AOR Lower 95% CI Upper 95% CI 
Pre-2014 2.81 2.45 3.72 
Post-2014 5.16 3.69 7.21 
The second subgroup analysis considered the length of time to follow-up, as studies included in the 
analyses had follow-up periods which ranged from 4 months to 2 years. However, as only two studies 
had follow-up periods of less than 1 year,40 44 including one study which had a very small sample size, 
the meta-analysis did not provide meaningful results.  
Finally, given the importance of the context of these studies (including social norms, regulatory 
environment, etc.), we conducted a subgroup analysis of the European studies as compared with the 
studies from the USA. As seen in Table 6, the AOR is higher in the European studies 39 40 44 48 as 
compared with the USA studies. 33 34 37 43 47     However the confidence intervals overlap. 
Table 6 Subgroup analyses of data collected from the USA and Europe 
Subgroup AOR Lower 95% CI Upper 95% CI 
USA studies 3.18 2.26 4.47 
European studies 6.22 3.73 10.38 
3.2.1.4 Population attributable fraction 
We calculated the population attributable fraction (PAF) for the high-quality studies included in the 





of the exposure (in this case e-cigarettes). It is used to assess the public health impact of the exposure 
(e-cigarettes) on conventional cigarette use. It is the percentage of cigarette smoking among the 
study population that used e-cigarettes that could be prevented if e-cigarettes were removed.26 In 
order to calculate the fraction for the included studies in this report, the following steps were taken: 
1. Used four high-quality studies,  
2. Converted AORs to risk ratios (RRs),27 and 
3. Calculated PAF using RRs 26 28 
Table 7 PAF for four studies 
Study ID Country AOR RR PAF 
Berry (2019)37 USA 4.09 3.66 14.89% 
Spindle (2017)43 USA 3.37 2.69 18.48% 
Wills (2017b)47 USA 2.87 2.61 12.04% 
Best (2018)48 UK 5.97 3.65 29.35% 
 
Table 7 shows that in the USA studies, between 12% and 18% of conventional smoking is attributable 
to e-cigarette smoking, while in the one UK study, this increases to 29% population attributable risk. 
However, it must be noted that there are limitations to the method used in this analysis,27 particularly 
the fact that the incidence rate used in the calculation is not adjusted, and as such, these results 
should be interpreted with caution29 30 
3.2.2 Past-30-day e-cigarette use 
Four studies examined the impact of past-30-day e-cigarette use at baseline and subsequent cigarette 
smoking at follow-up (Table 8). Using an adjusted model (including covariates from two of the three 
main domains), Hammond et al. (in a Canadian sample) found that those who had smoked e-
cigarettes in the past 30 days at baseline were more likely to have initiated smoking cigarettes at 
follow-up (AOR: 2.12; 95% CI: 1.68–2.66).50 Watkins et al. conducted their analysis using two separate 
models, adjusting for different amounts of covariates in each, also finding a positive association 
between past-30-day e-cigarette use and conventional cigarette use (AOR: 3.61; 95% CI: 1.82–7.16 
with 3 covariates, and AOR: 2.65; 95% CI: 1.38–5.1 with 14 covariates).38 Miech et al. also explored 
the association between those who had recently vaped (past 30-day use) and cigarette use at a 
follow-up (13.4 months later) in a USA sample (Table 9).51 Controlling for demographic and 
intrapersonal variables, they found a significant positive association between vaping and smoking 
(ARR: 4.78; 95% CI: 1.91–11.96).51 Finally, Spindle et al. (again in a USA sample), using a model which 
controlled for three of the main variable domains, also found a significant positive association 
between past-30-day e-cigarette use and ever cigarette use (OR: 3.41; 95% CI: 1.57–7.41).43 
A meta-analysis was conducted, including 30,018 participants from three of four studies measuring 
past-30-day e-cigarette use at baseline, and found a significant positive association between past-30-
day e-cigarette use at baseline and subsequent cigarette smoking initiation at follow-up (AOR: 2.14; 
95% CI: 1.75–2.62; I2 0%).38 43 50The forest plot is presented in Appendix 3. 
3.2.3 Past-30-day cigarette use 
Four papers (three unique studies) explored the association between e-cigarette use and past-30-day 
cigarette use (Table 8). Berry et al. used a model which adjusted for all three domains of covariates in 
a USA sample (the PATH Study) and found a significant positive association between e-cigarette use 
and past-30-day cigarette use at the 24-month follow-up point (AOR: 2.75; 95% CI: 1.6–4.73).37 
Watkins et al. used the same cohort, although with data from a 12-month follow-up point, to 





follow-up, using one model which adjusted only for alternative tobacco products and one model 
which adjusted for covariates in all three domains.38 E-cigarette use at baseline was associated with 
past-30-day cigarette use at follow-up (AOR: 2.39; 95% CI: 1.42–4.00 with 3 covariates, and AOR: 
1.87; 95% CI: 1.15–3.05 with 14 covariates).38 Spindle et al., using a sample from the USA, explored 
the associations between ever and past-30-day e-cigarette use with ever and past-30-day cigarette 
use at follow-up.43 Using a model which controlled for three covariate domains, they found a 
significant positive association between ever e-cigarette use and current (past-30-day) cigarette use 
(AOR: 3.3; 95% CI: 1.2–9.05).43 
Lozano et al.41 explored the association between ever e-cigarettes at baseline and past-30-day 
cigarette use at a 20-month follow-up in Mexico (Table 9). Using a model which adjusted for variables 
in all three covariate domains, they found a non-significant increase among e-cigarette users in 
cigarette use in the past 30 days (ARR: 1.43; 95% CI: 0.94–2.16).41 
3.2.4 Past-30-day e-cigarette and past-30-day cigarette use 
Two studies explored the association between past-30-day e-cigarette use and past-30-day cigarette 
use (Table 8). Spindle et al., using a sample from the USA, found that the association between past-
30-day e-cigarette use and past-30-day cigarette use was not significant (OR: 1.15; 95% CI: 0.15–
9.06).43 Similarly, Watkins et al., using data from the USA PATH Study, found no association for 3 
covariates (AOR: 2.48; 95% CI: 0.91–6.78) or for 14 covariates (AOR: 2.08; 95% CI: 0.81–5.4).38 
3.2.5 Frequency of e-cigarette and cigarette use 
Five studies explored the association between baseline e-cigarette use and frequency of subsequent 
smoking at follow-up (Table 8). Hammond et al.50 and Kinnunen et al.49 analysed the relationship 
between e-cigarette use at baseline and daily cigarette use, Hammond et al. at a 1-year follow-up, 
and Kinnunen et al. at a 2.5-year follow-up, both adjusting for demographic and intrapersonal 
variables.49 50 Hammond et al. found a significant positive association between baseline past-30-day e-
cigarette use and daily smoking initiation (AOR: 1.79; 95% CI: 1.41–2.28),50 while Kinnunen et al. 
found a significant positive association between ever use of nicotine e-cigarettes and daily smoking 
(AOR: 2.92; 95% CI: 1.09–7.85) but no association between ever use of non-nicotine e-cigarettes and 
daily smoking (AOR: 0.94; 95%CI 0.22-4.08).49 
Barrington-Trimis et al., using three cohort studies in California and Connecticut, explored the 
association between ever e-cigarette users at baseline and cigarette use (to varying degrees) at 
follow-up. They examined those who subsequently experimented with cigarettes (AOR: 4.57; 95% CI: 
3.56–5.87), those who were infrequent users of cigarettes (AOR: 4.27; 95% CI: 2.5–6.62), and those 
who frequently used cigarettes (AOR: 3.51; 95% CI: 1.97–6.24), controlling for demographic variables 
only; all findings demonstrated an increased likelihood of cigarette smoking.35 
Wills et al. explored the impact of different frequencies of e-cigarette use at baseline on smoking 
onset at follow-up.47 They found significant positive associations for one to two times e-cigarette ever 
use (OR: 2.88; 95% CI: 1.96–4.22), for three to four times e-cigarette use (OR: 2.29; 95% CI: 1.35–
3.87), for yearly/monthly use (OR: 4.17; 95% CI: 2.03–8.57), and for weekly/daily e-cigarette use (OR: 
4.09; 95% CI: 2.43–6.88).47 Leventhal et al., using a USA convenience sample, explored associations 
across different frequencies of e-cigarette use at baseline and cigarette use at follow-up.52 They found 
a positive association between baseline vaping and follow-up smoking frequency (AOR: 2.51; 95% CI: 
2.30–2.75), controlling for covariates in the three main domains.  
3.2.6 Nicotine versus non-nicotine e-cigarettes 
Two studies explored the specific impact of nicotine versus non-nicotine e-cigarettes on subsequent 
conventional cigarette use (Table 8). Adjusting for demographic and intrapersonal variables, one 
Dutch study found a significant positive association between ever use of e-cigarettes with nicotine 
and subsequent cigarette use (OR: 11.9; 95% CI: 3.36–42.12) and to a lesser extent between ever use 
of e-cigarettes without nicotine and subsequent cigarette use (OR: 5.36; 95% CI: 2.73–10.52).44 
Kinnunen et al. explored the association between ever trying either nicotine or non-nicotine e-





which controlled for demographic and intrapersonal variables, they found a positive significant 
association between ever use of nicotine e-cigarettes and daily smoking (OR: 2.92; 95% CI: 1.09–7.85) 


























Hammond et al. 
(2017)50 
Initiation Past-30-day use 2.12* 1.68 2.66 
Schools; age; sex; race/ethnicity; spending money; smoking status Y Y N 




Past-30-day use 1.79* 1.41 2.28 
Barrington-
Trimis et al. 
(2018a)35 
Experimented  Ever use  4.57* 3.56 5.87 
Sex; race and/or ethnicity; grade; study (e.g. cohort 1, 2 or 3) Y N N 
Barrington-
Trimis et al. 
(2018a)35 
Infrequent Ever use 4.27* 2.75 6.62 
Barrington-
Trimis et al. 
(2018a)35 
Frequent Ever use 3.51* 1.97 6.24 
Berry et al. 
(2019)37 
Past-30-day use Ever use 2.75* 1.6 4.73 
Sex; age; race/ethnicity; parental education; urban or rural 
residence; living with tobacco user; noticing tobacco warnings; 
tobacco advertisement receptivity; ever alcohol use; ever 
marijuana use; prescription drug abuse; enjoying frightening 
things; liking new and exciting experiences; preferring 
unpredictable friends; willingness to smoke in next year; curiosity 
about cigarettes; susceptibility to cigarette peer pressure from 
friends 
Y Y Y 
Watkins et al. 
(2018)38 
Ever use Former use 2.58* 1.77 3.761 
Hookah use; non-combustible cigarette use; smokeless tobacco 
use; gender; age; race/ethnicity; parental education; urban 
residence; sensation seeking; ever alcohol use; living with tobacco 
user; notice of cigarette warning labels; tobacco advertising 
receptivity; summer season 
Y Y Y Watkins et al. 
(2018)38 
Ever use Past-30-day use 1.87* 1.15 3.05 
Watkins et al. 
(2018)38 
























Watkins et al. 
(2018)38 
Past-30-day use Former use 1.84* 1.07 3.15 
Watkins et al. 
(2018)38 
Past-30-day use Past-30-day use 2.08¥ 0.81 5.4 




Ever use 2.51* 2.3 2.75 
Age; sex; ethnicity; highest parental education; whether student 
lived with both parents; ever use of alcohol or drugs; ever use of 
combustible tobacco product; family history of smoking; 
depressive symptoms; impulsivity: lack of premeditation; 
impulsivity: sensation seeking; delinquent behaviour; peer 
smoking; smoking susceptibility; smoking expectancies 
Y Y Y 
Spindle et al. 
(2017)43 
Ever use Past-30-day use 3.41* 1.57 7.41 
Gender; age; ethnicity; depression; anxiety; negative urgency; 
positive urgency; lack of premeditation; lack of perseverance; 
sensation seeking; stressful life events; peer deviance; other 
tobacco use 
Y Y Y Spindle et al. 
(2017)43 
Past-30-day use Ever use 3.3* 1.2 9.05 
Spindle et al. 
(2017)43 
Past-30-day use Past-30-day use 1.15¥ 0.15 9.06 
Wills et al. 
(2017b)47 
Ever use Use 1–2 times 2.88* 1.96 4.22 
Age; gender; ethnicity; parental education; parental support; 
rebelliousness 
Y N Y 
Wills et al. 
(2017b)47 
Ever use Use 3–4 times 2.29* 1.35 3.87 





4.17* 2.03 8.57 
Wills et al. 
(2017b)47 
Ever use Use weekly/daily 4.09* 2.43 6.88 






0.94¥ 0.22 4.08 
Gender; socioeconomic background (measured by parental 
background); other tobacco product use; school clustering 
























Kinnunen et al. 
(2019)49 
Daily smoking 
Ever use nicotine 
e-cigarettes 
2.92* 1.09 7.85 
*Statistically significant at the level determined by the study. ¥ Non-significant results at the level determined by the study. 
 






















Ever use 1.43¥ 0.94 2.16 
Sex; age; parent SES; sensation seeking; friends that smoke; parents that 
smoke; siblings that smoke; tried alcohol; binge drinking; Internet tobacco 
product advertising 
Y Y Y 
Miech et al. 
(2017)51 
Ever use Past-30-day use 4.78* 1.91 11.96 
Binge drinking in last 30 days [baseline]; marijuana used in last 30 days 
[baseline]; female; non-white 
Y N Y 
*Statistically significant at the level determined by the study.  






4 Discussion  
4.1 Summary findings 
The most commonly explored association among the included studies was between ever e-cigarette use and 
subsequent use of cigarettes. All studies which explored this relationship, other than Wills et al,45 found that there 
was a significant positive association between ever using an e-cigarette at baseline and ever using a cigarette at 
follow-up. Our meta-analysis which included 9 of the 14 unique studies and was based on primary study adjusted 
odds ratios, found that the combined odds of trying smoking were 4.06 times higher for those who had ever used e-
cigarettes at baseline, although this was reduced slightly (to 3.71 times the odds) when only the high-quality studies 
were included. The main meta-analysis indicated that the model had a moderate to high statistical heterogeneity; 
however, a sensitivity analysis of only high-quality studies had low to moderate statistical heterogeneity with a 
slightly reduced combined OR. Using the formula proposed by Zhang and Yu (1998),27 an approximation of an 
adjusted relative risk [risk ratio] was calculated for the four high-quality studies.37 43 47 48 This resulted in a range of 
values for the PAF, indicating that between 12% and 29% of those in the four studies who had tried a cigarette had 
done so due to their initial use of e-cigarettes. In other words, if e-cigarettes did not exist, there would have been 
between 12% and 29% fewer adolescent smokers. However, it must be noted that there are limitations to this 
method, in particular the fact that the incidence rate used in the calculation is not adjusted, and as such, these 
results should be interpreted with caution.29 30 Subgroup analyses of these studies revealed a higher OR for the data 
collected after 2014, a time point at which e-cigarette use increased substantially,10 as well as for the data collected 
in Europe (as compared with the USA). 
Based on primary study adjusted odds ratios, four studies examined the relationship between past-30-day e-
cigarette use and initiating cigarette use also found a significant positive association, although with a lower 
combined OR than ever trying e-cigarettes; indeed, a meta-analysis of three of these studies found that e-cigarette 
users had 2.14 times the combined odds of cigarette smoking compared with non-e-cigarette users. Three studies 
measured the association between ever e-cigarette use and past-30-day cigarette use, with significant  positive 
associations in the USA samples37 38 43 but no association in a Mexican sample.41 Neither study which measured past-
30-day use of e-cigarettes and subsequent past-30-day cigarette use found a significant positive association.43 38 
Different patterns of use and frequency of use of both e-cigarettes and cigarettes retained significant positive 
associations. One USA study found significant positive associations between e-cigarettes and ‘experimenters’, 
infrequent and frequent users of cigarettes.35 In the inverse, two USA studies examined different frequencies of e-
cigarette use at baseline on ever cigarette use at follow-up and found significant  positive associations between all 
variations of e-cigarette use and subsequent smoking.47 52 Two studies which examined the relationship between e-
cigarette use and daily cigarette use found a significant positive association, 49 50 although this relationship was non-
significant when non-nicotine e-cigarettes were examined.49 
Two studies explored the specific impact of nicotine versus non-nicotine e-cigarettes on subsequent conventional 
cigarette use.44 49 One study which measured ever e-cigarette use and ever smoking found a significant positive 
association between ever use of e-cigarettes with nicotine and subsequent cigarette use, and between ever use of e-
cigarettes without nicotine and subsequent cigarette use, although to a lesser extent.44 However, a study which 
explored the impact of nicotine versus non-nicotine e-cigarettes on daily smoking found a significant positive 
association with nicotine e-cigarettes, but no association between non-nicotine e-cigarettes and daily smoking.49 
We assigned a level of evidence of 3 using British Medical Journal guidelines,31 as this is a systematic review of 
cohort studies, some of which had high loss to follow-up and/or very small sample sizes. However, with respect to 
certainty of evidence,32 the HRB authors have moderate confidence that the true effect is probably close to the 
estimated effect for trying smoking at follow-up for those who had ever used e-cigarettes at baseline, as all meta-
analyses indicate that there is a significant positive association between using e-cigarettes at baseline and smoking 
cigarettes at follow-up, and this effect size is quite large; the findings are statistically significant, consistent and the 
exposure occurred before the outcome. Six studies controlled for confounding under three domains (demographic, 
interpersonal, and intrapersonal) associated with smoking cigarettes, and had a similar, but tighter, significant 
estimate of effect in meta-analysis. The four high-quality studies also had a similar and tighter estimate of effect and 
lower statistical heterogeneity. The remainder of the studies were judged to be moderate quality because of their 
small sample sizes and/or high loss to follow-up. The findings of the HRB meta-analysis are consistent with two 





4.2 Comparison with previous research 
4.2.1 Comparison with other systematic reviews 
A previous systematic review and meta-analysis, conducted in 2017, also examined the association between initial 
use of e-cigarettes and subsequent smoking.56 Although this study investigated both adolescents and young adults 
(with an age range of 14–30 years), many of the studies investigated were similar to the ones in the present review, 
albeit without the more recently published papers. Similarly to the HRB review, Soneji et al. found that e-cigarette 
use is associated with an increased risk of future cigarette smoking initiation and current cigarette smoking, even 
after adjusting for potential confounding by demographic, psychosocial and behavioural risk factors (AOR: 3.5; 95% 
CI: 2.38–5.16; I2 56%). The Soneji et al. meta-analysis included seven studies, whereas the HRB meta-analysis 
included nine studies56. We did not include three of the studies from the Soneji et al. meta-analysis. Miech et al. was 
not included in this meta-analysis because the data were analysed using RR and an ARR, and we could not convert 
the ARR to an AOR.51 The two Primack studies were excluded because their respondents’ average age exceeded 19 
years. The results also correspond to a more recent meta-analysis which found a significant positive association 
between e-cigarette use and subsequent smoking in a UK context only.57 Although we focused on adolescents only, 
other studies have found this positive association in older age groups such as Primack et al. and Unger et al. 
described in the meta-analysis by Soneji et al.56 A narrative review conducted by Glasser et al. (2019) concluded that 
while e-cigarette use is associated with subsequent smoking, it is difficult to draw strong conclusions because of 
methodological limitations, and urged future research to address vulnerabilities in young people which may explain 
the relationship.25 The World Health Organization based on the Academies of Sciences systematic narrative review 
reported that there is moderate evidence that young never-smokers who experiment with electronic cigarettes are 
at least twice more likely to experiment with smoking later.58 
4.2.2 Public health considerations with respect to e-cigarette use 
Soneji et al., in their systematic review, suggested that in order to minimise the potential public health harm from e-
cigarette use, regulatory authorities and public health agencies need to enforce age limitations when buying e-
cigarettes, place restrictions on advertising campaigns that may be viewed by adolescents, limit characterising 
flavours, and report nicotine content in e-liquid.56 Aladeokin and Haighton suggested that public health policy 
makers in the UK still need clear conclusions about the effects and safety of e-cigarettes.57 The EU has developed 
regulations to address e-cigarette manufacture, presentation and sales under the Tobacco Products Directive 
(2014/40/EU).59 The Directive lays down rules prohibiting sales to persons under 18 years. In addition, Article 20 of 
the new regulations prohibit promotional elements on e-cigarette packaging, and cross-border advertising and 
promotion of e-cigarettes, sets limits on maximum concentrations of nicotine in liquids, limits maximum volumes of 
liquid that can be sold in a single container, requires childproof and tamper-proof packaging of liquid, sets 
requirements on purity of ingredients, requires that the devices deliver consistent doses of vapour, requires 
disclosure of ingredients and nicotine content, and allows member state regulators to act if the regulations are 
violated. In addition, warning labels can be placed on e-cigarettes. However, the regulations do not ban vaping in 
public places.59 Ireland are in the process of implementing the European regulations. A population health approach, 
similar to that successfully used in Ireland to address tobacco, alcohol and psychoactive drug issues may need to be 
extended to tackle use of e-cigarettes; a population health approach to psychoactive substances usually involves 
addressing price, availability, and marketing to limit use among young and vulnerable populations. Kennedy et al. 
reviewed the global approaches to regulating e-cigarettes and found that 22 countries regulate e-cigarettes using 
existing regulations, 7 countries made amendments to existing legislation, and 14 countries use a combination of 
new/amended and existing regulation. In addition, 25 countries enacted new policies to regulate e-cigarettes.60 
Kennedy et al. identified several regulation domains including product prohibitions or restrictions related to e-
cigarette manufacturing, distribution, importation, sale and minimum age of purchase; They also identified use 
restrictions on use including vape-free public places. They identified that a number of countries prohibited or 
restricted advertising, promotion, and/or sponsorship.60 Some countries introduced taxation of e-cigarettes to 
increase price or affordability. Some countries introduced requirements such as health warning labelling, listing of 
ingredients including flavours, listing nicotine volume/concentration, reporting of adverse events associated with e-
cigarettes and their liquids, and the introduction of child-safety packaging. Kennedy et al. also found that e-
cigarettes were banned in 25 countries and market authorisation was required in 17 other countries.60 The authors 
go on to say that minimum age-of-purchase policies was common in countries permitting the sale of e-cigarettes 





public spaces such as bars, restaurants and other workplaces in 25 countries. Advertising and promoting e-cigarettes 
were banned in 35 countries.60 
Kennedy et al. identified 14 countries that required e-cigarettes to have health warning labels, and 13 that regulated 
ingredients and flavours that were to be used in e-cigarettes.60 In 14 countries, nicotine concentrations did not 
exceed 20 mg/mL of e-liquid. Child-safety standards for e-cigarettes and/or e-liquid bottles were required in 11 
countries. Regulations on importation of e-cigarettes were in place in 14 countries. Manufacturing standards for e-
cigarettes marketed as medicines were required in 13 countries.60 The distribution of e-cigarettes marketed as 
medicines was regulated in 21 countries. Manufacturers/retailers are required to notify the appropriate authority 
prior to marketing e-cigarettes in 13 countries. Specific safety standards were required for e-cigarettes or e-liquids in 
26 countries. Venezuela prohibited the registration of e-cigarettes as a brand/patent. Six countries applied a tax to e-
cigarettes. The list of regulatory options identified by Kennedy et al. provides policy makers with a broad menu of 
possibilities.60  
4.3 Theoretical implications 
It is clear from the above results that there is a strong positive association between e-cigarette use and subsequent 
cigarette trial; however, it is not clear what is driving this association. One commonly proposed explanation is the 
‘gateway theory’, which was developed by Denise Kandel in the 1970s as a hypothesis to explain the observed 
phenomenon of young people’s use of alcohol and drugs in specific stages and sequences.61 The theory has been 
developed since then, most recently exploring the effects of nicotine on the brains of mice, and had been applied to 
the e-cigarette debate: 
 
However, the gateway theory has received criticism, both in general and in relation to e-cigarettes.62 63 A commonly 
reported refrain from detractors of the gateway theory is that it is difficult to test.63 Etter states that Hill’s (1945) 
nine aspects of causality need to be employed in order to decide whether an association is causal: 1) strength of the 
association; 2) consistency (across trials, investigators, individuals, research methods, replications); 3) specificity (can 
other things cause it?); 4) temporal precedence (do we know if cause precedes effect?); 5) dose responsivity; 6) 
plausibility (biological and psychological); 7) coherence (consistent with other lines of evidence); 8) experiment; and 
9) analogy (do similar agents act similarly?).63 
In order to try to explore the roots of causality, Etter recommends large longitudinal epidemiological studies which 
measure smoking onset, control for confounders, and include a propensity score measure of liability to smoking. 
Many of the studies included in this review are designed as such; indeed, some (such as Treur et al.44) have explicitly 
addressed Etter’s suggestions of study characteristics that are needed to provide evidence for this theory.44 63 
Others, such as Berry et al.,37 have demonstrated that propensity for risk is unlikely to be the sole reason for 
initiation in this gateway, as the association in their study was especially pronounced in the low-risk group. Some 
studies have evaluated other aspects, such as dose responsivity. Wills et al.47 and Leventhal et al.52 provided some 
evidence for different frequencies of vaping at baseline, but this result needs to be further explored. The study 
design used to assess the relationship between e-cigarette use and initiation of cigarette smoking does not allow us 
to say there is a definitive causal relationship but it does allow us to say that the findings build a case towards a 
causal relationship as the findings are consistent across all studies included in the meta-analysis. Furthermore, the 
strength of association is statistically significant across all primary research studies. In addition, the use of e-
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Our findings also provide initial biologic insights that may help inform the current 
debate about electronic cigarettes, which have been promoted as a tool to stop 
smoking and reduce the harmful effects of combustible tobacco use in the 
population. Although e-cigarettes eliminate some of the morbidity associated with 
combustible tobacco, they and related products are pure nicotine-delivery devices. 
They have the same effects on the brain as those reported here for nicotine, …and 





cigarettes occurred before initiating smoking fulfilling the criteria for a temporal relationship and two studies have 
examined the dose response relationship.  
Whether there are other additional explanatory factors or not, we need to understand what drives the relationship 
between e-cigarette and tobacco cigarette use and if the effect is definitively causal. Critics of the gateway theory 
often propose the common liability theory, which states that there is an underlying common liability within people 
which increases their propensity to use drugs. 64-67  Despite this, one strong argument against the common liability 
theory is that some studies have shown that young people with typically low risk of initiating smoking have reported 
the strongest association between e-cigarette use and subsequent smoking. Indeed, studies included in this review 
have found this; for example, Morgenstern et al. found, in a German sample, that the association between e-
cigarettes and subsequent smoking initiation was stronger among adolescents with low sensation-seeking scores and 
without any experience of alcohol intoxication.42 Similarly, in a Canadian sample, Aleyan et al.53 found that the 
relationship between e-cigarette use and subsequent smoking was stronger among non-susceptible young people 
than susceptible young people – a result that mirrored Barrington-Trimis et al.’s (2016)34 finding that associations 
were stronger in adolescents with no intention of smoking at initial evaluation. Berry et al. also found that the 
association of prior e-cigarette use with cigarette initiation was stronger among low-risk youths, and Wills et al. 
(2017a) found that the relation between e-cigarette use at one time point and smoking onset at a subsequent time 
point was stronger among participants with lower levels of rebelliousness and willingness and higher levels of 
parental support.37 46 Conner et al. (2018) found that the association between ever use of e-cigarettes and initiation 
of cigarette use was particularly strong among adolescents with no friends who smoked, a group usually considered 
to be less susceptible to smoking initiation.39 Furthermore, Miech et al. found that among never-smokers at baseline, 
recent vapers were more than four times more likely to move away from the perception of cigarettes as posing a 
‘great risk’ of harm, a finding consistent with a desensitisation process.51 These findings are concerning, as they 
highlight the risk that e-cigarettes, and subsequently cigarettes, may be introduced to a population who otherwise 
would never have used e-cigarettes.2 It also highlights that propensity for risk may not be driving the association 
between e-cigarettes and subsequent smoking.37 
Recently, however, some authors have proposed that the gateway theory and the common liability theory are not, 
as some say, opposing, but rather are complementary.1 2 They state that use of drugs in general will be explained by 
common factors, whereas specific factors will explain why young people use drugs in a specific sequence.1 
4.3.1 Catalyst model 
In a 2016 paper, Schneider and Diehl proposed an alternative model for the path from e-cigarette use to 
conventional cigarette use, considering numerous hypotheses and pathways. They separate the process into two 
stages, from no consumption to e-cigarette consumption, and then from e-cigarette use to conventional cigarette 
use (Figure 4).62(p651) Factors such as flavour, health, price, role model, concealment, and acceptance play a role in 
the first stage by easing the process of initiation, as they appear healthier and more acceptable to some, while the 
flavours attract others. In the second stage (i.e. the transition from e-cigarettes to cigarettes), the authors 
hypothesise that addiction, accessibility, and experience may drive the subsequent move to conventional cigarette 
use.62 
The addiction element of this model hypothesises that the addictive nature of nicotine will potentially encourage 
young people who have developed a tolerance to the nicotine provided by e-cigarettes to transition to conventional 
cigarettes due to a desire to increase the nicotine dose. This hypothesis is particularly relevant in relation to 
adolescents, due to the believed sensitivity of the developing brain to the effects of nicotine. The experience 
element hypothesises that familiarising young people with the habitual rituals associated with e-cigarettes could 
familiarise and ingratiate them with the similar processes associated with conventional cigarettes. Finally, the 
accessibility and proximity of both e-cigarettes and cigarettes may work to promote conventional cigarettes to e-
cigarette users. For young people, the proximity to smokers, as an e-cigarette user, may be particularly important. 
This model demonstrates that there are a number of paths whereby e-cigarette use might encourage smoking 
uptake. 
Two factors which exist outside the model but are nevertheless influential are the liability hypothesis and the 
renormalisation hypothesis. The liability hypothesis states that “individual predisposition and specific socialization 
make the initiation of e-cigarette and tobacco use more likely, especially among adolescents”62(p650} and the 
renormalisation hypothesis states that “the increasing rate of e-cigarette use leads to the renormalization of 






Figure 4 Schneider and Diehl’s illustration of the possible catalyst function of e-cigarettes, along with possible 
reasons for potential transitions 
Used with permission. © The Author 2015. Published by Oxford University Press on behalf of the Society for 
Research on Nicotine and Tobacco. Source: Schneider and Diehl,62(p651) 
4.4 Limitations 
As with any research study, there are some limitations to this systematic review, with regard to both the overall 
review and the included studies. 
4.4.1 E-cigarettes as standard exposure 
One limitation of the research in this area is the lack of specificity of the exposure (e-cigarette) in terms of 
generation, product type, e-liquid and its nicotine content, etc. None of the included studies asked specific 
questions, and only two44 49 of the 21 studies measured the differences between nicotine and non-nicotine e-
cigarettes. This is particularly pertinent as the world of e-cigarettes is fast-moving, with new products developing 
rapidly. As the data in this review were collected between 2013 and 2016, it is possible that the collected data refer 
to e-cigarette products which are no longer in widespread use. Future cohort studies will need to collect more 
detailed information on young people’s e-cigarette use in order to increase our knowledge in this area. 
In addition, given that the baseline data of many of these studies were collected in locations and at times when 
there were no age restrictions on e-cigarettes, it is possible that the e-cigarette use pattern may already have 
changed.68 69  
4.4.2 Exposure and outcome measures 
The most common measure of both e-cigarette and cigarette use was ‘ever use’ of either product, a measure which 
has been criticised by commentators.63 ‘Past-30-day use’ has received the same criticism, as it does not identify 
whether people used the product once in the past 30 days, or if they used it regularly. However, the use of these 
measures has been justified by a number of publications, with a recent study by Birge et al. reporting that more than 
two-thirds of smokers who tried as little as a single puff during adolescence became, for a time, regular smokers.70 In 
adolescents specifically, Dierker et al. (2012) report that a usual trajectory of smoking proceeds from 





Furthermore, one of the studies included in this review, East et al., used a causal mediation analysis, finding that e-
cigarette escalation did not act as a mediator between ever use of cigarettes and subsequent smoking, which 
suggests that it is primarily ever use of e-cigarettes that contributes to initiation of use of cigarettes.40 
Given the limited data collection points in these studies, it is possible that a proportion of e-cigarette non-users at 
baseline may have initiated e-cigarette use during the follow-up periods of the studies, but will continue to be 
labelled as non-users, thereby underestimating the exposure. Secondly, as pointed out by Berry et al., by examining 
an exposure that is already established at baseline and adjusting for alcohol and marijuana use at that time point, 
studies may fail to account for variables that fall in the pathway between exposure and outcome.37 Evidence from 
Wills et al. demonstrates that the temporal sequence of confounders can have an impact.45 Future research should 
focus on following young people for longer, collecting more detailed data at multiple points in order to assess the 
patterns of use. 
Finally, in all the studies in this area, it must be noted that self-reporting of smoking may result in under-reporting of 
smoking levels by young people.72  
4.4.3 The issue of confounding and causality 
It should be noted that all of the studies included in this review are observational prospective cohort studies with 
one or two follow-up points. As such, these studies are good for testing the sequence of events but cannot explain 
why this association is happening.1 Many of these studies included the known potential confounding variables (e.g. 
social status, smoking susceptibility, peers who smoke), but of course, there could be other underlying 
characteristics which have not been accounted for in these models. One study, funded by the tobacco industry, 
conducted many exploratory analyses of the USA PATH Study data in order to better understand the impact of 
confounding variables in general, with a particular focus on propensity-to-smoke scores. They concluded that 
reported estimates of the gateway effect are too high and argued that the effect may not be seen if all confounding 
variables are fully accounted for.73 Furthermore, it has been noted that although several studies ask questions 
assessing the respondents’ sensation seeking, impulsivity, or rebelliousness, their actual illicit substance use (which 
was less frequently included) may be a better, more tangible measure.74 
As it is unlikely that RCTs would be possible in this area (due to the ethical conundrum of providing young people 
with e-cigarettes), causality will be difficult to prove;63 however, autoregressive and causal mediation analyses, such 
as those carried out by Wills et al.45 and East et al.,40 may help us to unpick the underlying factors which drive the 
association between use of e-cigarettes and subsequent smoking. These may help to further the case for causality. 
4.4.4 Limitations of specific studies 
Four studies that measured use of e-cigarettes at baseline and ever smoking between baseline and follow-up were 
considered to be of high quality,37 43 47 48 and were included in our sensitivity analysis.  
A recurring issue across our studies was the use of convenience, matched, or quota samples, which restricts the 
representativeness of the findings. 33-35 39 40 50 52 A further common limitation was the high loss to follow-up rates in 
the included studies, with only five papers retaining more than 80% of their sample at follow-up. 33 37 38 42 52 
In addition to the more common issues, some studies had specific problems which may inhibit interpretation of their 
findings. One study, conducted in the Netherlands, carried out its longitudinal analysis on a subset of its sample (less 
than one-third). However, although the authors provided demographic information on the overall sample, they did 
not provide information on this subset. This is problematic for assessing the study’s representativeness.44 Finally, 
one USA study, conducted by Spindle et al., presented incorrect data in the Table 2 presented in their paper.43  
4.5 Future research 
4.5.1 Cigarette escalation  
In this review, we specifically investigated cigarette-naive young people at baseline. However, interesting studies, 
such as those conducted by Bold et al.75 Conner et al.,39 and Chaffee et al.,76 have investigated escalation of cigarette 
use among young e-cigarette users. For example, Chaffee et al. (2018) found that e-cigarette use was associated 
with progression from experimental smoking to established cigarette smoking among adolescent cigarette 





4.5.2 Future patterns of smoking 
As outlined by Etter, one of Hill’s requirements for ascertaining causality is the investigation of the dose-frequency 
response.63 Kinnunen et al. state that in order to test the gateway theory, initiation, ever use, and regular use need 
to be explored.49 They found that nicotine e-cigarette experimentation or use, but not non-nicotine e-cigarette 
experimentation or use, predicts the onset of daily cigarette smoking, and that nicotine e-cigarette experimentation 
predicts the daily use of nicotine e-cigarettes. 
This study provides evidence towards establishing the link between e-cigarette use and the onset of smoking. The 
next stage of this association is to consider whether e-cigarette use at a young age has any impact on the 
subsequent frequency of, and dependency on, cigarette smoking. Some studies have already investigated this, but 
further work needs to be done in order to synthesise these results, facilitating a deeper and more robust 
examination of this relationship.  
The studies which examined different frequencies of the exposure (e-cigarette vaping) and the outcome (cigarette 
smoking) found significant positive associations, but further research is needed in order to build a body of 
knowledge. Furthermore, exploration of whether smoking during the follow-up period is associated with later 
dependent smoking is warranted.74 
4.5.3 Vaping and smoking in different contexts 
Given differences between USA and Europe results, future research should consider the impact of context. European 
adolescents who appear to have a higher incidence of smoking initiation following e-cigarette use than adolescents 
in the USA.  
Recent research has found that adolescent e-cigarette users, which are generally considered less susceptible and at 
lower risk potentially, demonstrates the strongest association between e-cigarette use and subsequent smoking 
such as that reported by four of our included studies.37 39 46 51. Consequently, we can see that this may result in a 
generation of vapers and smokers who would otherwise not have ever used cigarettes – something which needs 
careful consideration at a public health level. That said, some authors note the need to take a population health 
approach when examining the potential impact, pointing out that even if the gateway theory is true, there are such 
low numbers of vapers among never users of cigarettes that the aggregate risk is small, and questioning whether it is 
ethical to restrict e-cigarette use. 54 63  However, in response, Chapman et al. warn that even if the numbers of e-
cigarette users are currently low, this may change in response to the industry’s marketing efforts.2 They state: 
 
4.5.4 What is causing the association? 
It is very clear that there is a positive association between use of e-cigarettes and use of cigarettes. However, there is 
a need to better understand the roots of this association – is there a gateway, or a common liability hypothesis, or is 
it explained by the catalyst model or combinations of these theories? Despite fierce debates on the merits of 
different theories, no consensus has been reached on the most likely explanation. Future research should focus on 
designing studies which specifically set out to test these theories (or elements thereof). It would be beneficial for 
future research to attempt to isolate and unpick elements of Schneider and Diehl’s model in order to test them and 
further our understanding of this association.62  
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The public health test of the importance of this if it occurs will be the absolute 
numbers involved. The current evidence about this issue is limited by the short time 
frame of the introduction of e-cigarettes into a market that has other nicotine-based 
products, to fully understand their effects on these products and their users. It is 
also limited by the fast evolution of e-liquids, and their delivery technology, as well 
as the scarcity of evidence regarding the potential effects of regulations on the role 
of these products in the marketplace for nicotine. Notwithstanding, the available 
evidence provides an unequivocal cause for caution about e-cigarettes’ role as a 
harm reduction product given the emerging evidence in support of their gateway 






Wills et al. (2016) used structural equation modelling analysis to unpick social and cognitive factors in the 
relationship between e-cigarette use and subsequent cigarette use.45 They found that there was no significant direct 
effect of e-cigarette use on subsequent smoking, with marijuana use and smoking expectancies accounting for much 
of the variance, potentially supporting the common liability model. However, others, such as Berry et al. (2019), 
demonstrated that propensity for risk is unlikely to be the sole reason for initiation in this gateway, as association 
was especially pronounced in the low-risk group, and East et al. used a causal mediation analysis to suggest that it is 
primarily ever use of e-cigarettes that contributes to the initiation of cigarette smoking.37 40 Chapman et al. report 
that there is both discordance and disagreement in this field, with authors engaged in a debate as to whether the 
gateway theory applies to e-cigarette users who go on to initiate smoking cigarettes, if it is possible to test, or if 
there are other theories which would better explain the relationship between e-cigarette use and subsequent 
smoking.2 
Unfortunately for policy-makers, we need to conduct more research which attempts to unpick the specific social and 
cognitive covariates which contribute to (or drive) the relationship between e-cigarette use and subsequent 
smoking, such as the structural equation modelling conducted by Wills (2016).45 In order for policy-makers to make 
decisions about the impact of e-cigarettes, they need to understand why e-cigarettes are associated with smoking. 
We suggest exploring the association using both explorative quantitative and qualitative research approaches. 
 
Conclusions 
We found a four-fold association between ever using e-cigarettes and initiating smoking tobacco cigarettes in 
adolescents in a combined analysis of nine cohort studies conducted with follow-up periods between 4 and 24 
months. Sensitivity and subgroup analysis support the association between ever using e-cigarettes and initiating 
smoking tobacco cigarettes. The study design used to assess the relationship between e-cigarette use and initiation 
of cigarette smoking does not allow us to say there is a definitive causal relationship, but it does allow us to say that 
the findings builds a case towards a causal relationship as the findings are consistent across all studies included in 
the meta-analysis. Furthermore, the strength of association is statistically significant across all primary research 
studies in the meta-analysis. In addition, there use of e-cigarettes occurred before initiating smoking fulfilling the 
criteria for a temporal relationship and two studies have examined the dose response relationship. Moreover, the 
results of this systematic review are in line with the previous systematic reviews and meta-analyses. Whether there 
are other additional explanatory factors or not, we need to understand what drives the relationship between e-
cigarette and tobacco cigarette use and if the effect is definitively causal. One author recommends large longitudinal 
epidemiological studies which measure smoking onset, control for confounders, and include a propensity score 
measure of liability to smoking. Other authors suggest exploring the association using qualitative research 
approaches.  
We identified three theories that attempt to explain the move from using e-cigarette use to smoking tobacco 
cigarettes, and these are: the gateway theory, the common liability theory, and the catalyst model. The gateway 
theory was developed to explain the observed phenomenon of young people’s use of alcohol and drugs in specific 
stages and sequences, and intimates that e-cigarette use leads to conventional cigarette use. The common liability 
theory states that there is an underlying common liability within people which increases their propensity to use 
What do we know and what do we need to do now? 
We know that there is an association between using e-cigarette and initiating smoking cigarettes 
among adolescents, but we need to: 
• Understand what drives the association or relationship between e-cigarette and cigarettes 
• Explore the frequency and patterns of use of e-cigarettes and explain their relationship 
with subsequent smoking cigarette  
• Explore the role of e-cigarettes and illicit substance use 





drugs and other illicit substances and that the move from e-cigarettes to conventional cigarettes or other drugs is 
part of their risk behaviours. Recently, however, some authors have proposed that the gateway theory and the 
common liability theory are not, as some say, opposing, but rather are complementary. They state that use of drugs 
in general will be explained by common factors, whereas specific factors will explain why young people use drugs in 
a specific sequence. In a 2016 paper, two authors proposed an alternative model, the catalyst model, to explain the 
path from e-cigarette use to conventional cigarette use, considering numerous hypotheses and pathways. They 
separate the process into two stages, from no consumption to e-cigarette consumption, and then from e-cigarette 
use to conventional cigarette use. Factors such as flavour, health, price, role model, concealment, and acceptance 
play a role in the first stage by easing the process of initiation, as they appear healthier and more acceptable to 
some, while the flavours attract others. In the second stage (i.e. the transition from e-cigarettes to cigarettes), the 
authors hypothesise that addiction, accessibility, and experience may drive the subsequent move to conventional 
cigarette use. Two factors which exist outside the model but are nevertheless influential are the [common] liability 
hypothesis and the renormalisation [of smoking] hypothesis. Despite fierce debates on the merits of different 
theories, no consensus has been reached on the most likely explanation. Future research should focus on designing 
studies which specifically set out to test these theories (or elements thereof). It would be beneficial for future 
research to attempt to isolate and unpick elements of Schneider and Diehl’s Catalyst model that describes e-
cigarette initiation and subsequent cigarette use in order to further our understanding of this relationship.  
The EU has developed regulations to address e-cigarette manufacture, presentation, and sales under the Tobacco 
Products Directive (2014/40/EU). Ireland are in the process of implementing the European regulations. A population 
health approach, similar to that successfully used in Ireland to address tobacco, alcohol and psychoactive drug issues 
may need to be extended to tackle use of  e-cigarettes; a population health approach to psychoactive substances 
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Appendix 1: Literature search strategies and results 
List of databases and resources used 
1. Ovid Medline 
2. Cochrane Library 
3. Ovid PsycInfo 
4. Elsevier Embase 
5. NHS NIHR PROSPERO 
6. LILACS 
7. Google Scholar 
8. CORE.ac.uk 
9. List of reviews and reports used for citation searching 
 
Results from each database 




Duplicates excluded from each 
database  
Total 14676 6510 8166 
Ovid Medline 3874 3690 184 
Cochrane Central 527 274 253 
Cochrane Systematic 
Reviews Database 
14 12 2 
PsycInfo 1519 369 1150 
Embase 4212 1391 2821 
PROSPERO 93 93 0 
LILACS 4042 558 3506 
Google Scholar 200 43 157 
CORE 192 80 112 
 
1. Ovid Medline search strategy and results  
 
Ovid Medline: E-cigarettes and heat-not-burn products  
Database Ovid MEDLINE(R) and Epub Ahead of Print, In-Process & Other Non-Indexed Citations, 
Daily and Versions(R) 1946 to April 12, 2019  
Date of Search 15.04.2019 




Language limits None used in the search 
Date limits None, apart from the limits set by the invention of e-cigarettes (2003-4) and heat-not-
burn products (approximately 1988 in their current forms) 
Study types Exclude animal models, cell lines 
Publication 
types 
Exclude commentary, editorials, replies. Letters are not outright excluded as research 








Search term Results 
E-cigarettes 1 Vaping/ 291 
2 Electronic Nicotine Delivery Systems/ 2293 
3 "Nebulizers and Vaporizers"/ and (nicotine or tobacco).mp. 155 
4 e-cig$.mp. 3087 
5 Ecig$.mp. 80 
6 (Vape or vaping or vaper or vapers).mp. 853 
7 (Vapori#e$ adj3 (cigarette$ or nicotine)).mp. 77 
8 ((electric or electronic) adj2 (cig$ or nicotine or tobacco or 
smoking)).mp. 
3496 
9 (e-sigaret$ or "e-sígarett$" or een sigaret$ or E-Zigarette$ or 
"cigarette$ électronique$" or "L'e-cigarette" or vapoteuse$ or 
"cigarrill$ electrónico$" or sigarett$ elettronic$ or sigarett$ 
elettronik$ or sigarett$ elettroniche$ or elektronik$ sigar$ or e-
savuke$ or e-rokok$ or rokok$ elektronik$ or e-papieros$ or e-
ugwayi).mp. 
55 
10 (mods adj5 (tobacco or nicotine)).mp. 2 
11 Juul$.mp. 40 
12 (e-juice$ or e-liquid$).mp. 392 
13 (cig-a-like$ or cigalike$ or ciga-like$).mp. 36 
14 (e-hookah$ or electronic hookah$ or "hookah pens").mp. 19 
15 (ENNDS or electronic non-nicotine delivery).mp. 3 
16 ((NMNDS and nicotin$) or non-medicinal nicotine delivery 
system$).mp. 
0 
17 or/1-16 4520 
Heat-not-burn 
products 
18 (Heated tobacco product$ or tobacco heating product$ or 
tobacco heating system$).mp. 
118 
19 ("heat-not-burn" or "heat not burn" or "heat notburn" or 
"heatnot burn").mp. 
83 
20 (Heatsticks or heat-sticks or tobacco sticks or Neosticks).mp. 13 
21 ((HEETS or Fiit or glo) adj3 (tobacco or nicotine or smok$)).mp. 2 
22 (IQOS or iFuse or Ploom).mp. 70 
23 (electrically-heated smoking system and (nicotin$ or 
tobacco$)).mp. 
1 
24 (Vapotage or "tabac chauffé" or "verhitte tabak" or "riscaldatori 
di tabacco" or "tabacco riscaldato" or "erhitzter Tabak" or 
"verhit tabak" or "zahřátý tabák" or "opvarmet tobak" or 
"oppvarmet tobakk" or "uppvärmd tobak" or "kuumutatud 
tubakas" or "pinainit na tabako" or "lämmitetty tupakka" or 
"shan taba mai tsanani" or "hitað tóbak" or "apsildāmā tabaka" 
or "tembakau dipanaskan" or "šildomas tabakas" or "tembakau 
yang dipanaskan" or "te taakapa" or "podgrzewany tytoń" or 
"tabaco aquecido" or "încălzit tutunul" or "zahriaty tabak" or 
"ogrevani tobak" or "tabaco caliente" or "ısıtılmış tütün" or 
"ugwayi ovuthayo" or "thuốc lá nóng").mp. 
11 




26 17 or 25 4645 
Basic animal 
and cell studies 
search 
27 animals/ not humans.sh. 4536484 
28 exp animals, laboratory/ or exp Animal experimentation/ or exp 






29 (animal adj2 (model$ or stud$ or experiment$ or 
laboratory)).ti,ab,kf. 
231870 
30 (Cat or cats or feline or dog or dogs or canine or rat or rats or 
Wistar or Sprague-Dawley or rodent$ or mouse or mice or 
murine or zebrafish or fish or chicken$ or horse$ or rabbit$ or 
"C. elegans" or caenorhabditis elegans or nematod$ or Xenopus 
or bird or birds or reptil$ or livestock or larva$).ti,ab,kf. 
3615741 
31 exp In Vitro Techniques/ or exp Biological Assays/ or exp cells, 
cultured/ or exp clinical laboratory techniques/ or Chemistry 
techniques, analytical/ or chemistry techniques, synthetic/ 
4144439 
32 ("in vitro" or biological assay$ or cell culture or cultured cells or 
cell lines or cell transformation assay$).ti,ab,kf. 
1414252 




cell or animal 
studies 
34 26 not 33 4284 
Publication type 35 (comment or editorial or note).pt. 1105825 
36 (reply or commentary or comment or editorial).ti. 135049 









38 34 not 37 3874 
 
2. Cochrane Systematic Reviews and Cochrane Central search strategy and 
results 
Cochrane Library: E-cigarettes and HeatNotBurn devices 
Database John Wiley & Sons Cochrane Library 
Date of Search 15.04.2019 




Language limits None used in the search 
Date limits None, apart from the limits set by the invention of e-cigarettes (2003-4) and HeatNotBurn 









Search terms Results 
E-
cigarettes 
#1 MeSH descriptor: [Vaping] explode all trees 10 
#2 MeSH descriptor: [Electronic Nicotine Delivery Systems] explode all 
trees 
72 
#3 MeSH descriptor: [Nebulizers and Vaporizers] explode all trees 2218 
#4 ((nicotine OR tobacco)):ti,ab,kw 10856 
#5 #3 AND #4 31 
#6 (e-cig*):ti,ab,kw 309 
#7 (ecig*):ti,ab,kw 309 
#8 ((vape OR vaping OR vaper OR vapers)):ti,ab,kw 66 
#9 (((vaporise OR vaporised OR vaporiser OR vaporize OR vaporized OR 
vaporizer) NEAR/3 (cigarette* OR nicotine))):ti,ab,kw 
18 
#10 (((electric or electronic) NEAR/2 (nicotine or tobacco or smoking or 
cig*))):ti,ab,kw 
321 
#11 ((e-sigaret* OR "e-sígarett*" OR E-Zigarette* OR "cigarette* 
électronique*" OR "L'e-cigarette" OR vapoteuse* OR "cigarrill* 
electrónico*" OR sigarett* elettronic* OR sigarett* elettronik* OR 
sigarett* elettroniche* OR elektronik* sigar* OR e-savuke* OR e-rokok* 
OR rokok* elektronik* OR e-papieros* OR e-ugwayi)):ti,ab,kw 
9 
#12 ((mods NEAR/5 (nicotine OR tobacco))):ti,ab,kw 0 
#13 (Juul*):ti,ab,kw 11 
#14 (e-juic* OR e-liquid*):ti,ab,kw 48 
#15 ((cig-a-like* OR cigalike* OR ciga-like*)):ti,ab,kw 4 
#16 (e-hookah* OR "electronic hookah" OR "electronic hookahs" OR 
"hookah pen" OR "hookah pens"):ti,ab,kw 
2 
#17 (ENNDS OR "electronic non-nicotine delivery"):ti,ab,kw 0 
#18 ((NMNDS AND nicotin*)):ti,ab,kw 0 
#19 (non-medicinal nicotine delivery system*):ti,ab,kw 0 
#20 #1 OR #2 OR #5 OR #6 OR #7 OR #8 OR #9 OR #10 OR #11 OR #12 OR 





#21 ("heated tobacco" OR "tobacco heating"):ti,ab,kw 43 
#22 (Heated tobacco product* OR tobacco heating product* OR tobacco 
heating system*):ti,ab,kw 
70 
#23 ("heat-not-burn" OR "heat not burn" OR "heat notburn" OR "heatnot 
burn" OR "heatnotburn"):ti,ab,kw 
6 
#24 (Heatsticks OR heat-sticks OR "heat sticks" OR tobacco sticks OR 
Neosticks):ti,ab,kw 
9 
#25 (IQOS or iFuse or Ploom):ti,ab,kw 17 
#26 ((Vapotage OR "tabac chauffé" OR "verhitte tabak" OR "riscaldatori di 
tabacco" OR "tabacco riscaldato" OR "erhitzter Tabak" OR "verhit 
tabak" OR "zahřátý tabák" OR "opvarmet tobak" OR "oppvarmet 
tobakk" OR "uppvärmd tobak" OR "kuumutatud tubakas" OR "pinainit 
na tabako" OR "lämmitetty tupakka" OR "shan taba mai tsanani" OR 
"hitað tóbak" OR "apsildāmā tabaka" OR "tembakau dipanaskan" OR 
"šildomas tabakas" OR "tembakau yang dipanaskan" OR "te taakapa" 
OR "podgrzewany tytoń" OR "tabaco aquecido" OR "încălzit tutunul" or 
"zahriaty tabak" OR "ogrevani tobak" OR "tabaco caliente" OR "ısıtılmış 
tütün" OR "ugwayi ovuthayo" OR "thuốc lá nóng")):ti,ab,kw 
7 
#27 ((HEETS or Fiit or glo) NEAR/3 (tobacco or nicotine or smok*)):ti,ab,kw 1 
#28 (("electrically-heated smoking system" AND (nicotin* OR 
tobacco*))):ti,ab,kw 
1 

















3. Ovid PsycInfo search strategy and results 
Ovid Medline: E-cigarettes and HeatNotBurn devices 
Database Ovid PsycInfo 
Date of Search 15.04.2019 
Age limits None used in the search 
Geographic limits None 
Language limits None used in the search 
Date limits None, apart from the limits set by the invention of e-cigarettes (2003-4) and HeatNotBurn 
(approximately 1988 in their current forms) 
Study types NOTE: did not remove animal or publication type items from Psycinfo as after testing, very few 
animal studies, and publication types filter removed useful items also. 





Search terms Results 
E-
cigarettes 
1 exp Electronic cigarettes/ 897 
2 ((Nebulizer$ or Vaporizer$) adj5 (nicotine or tobacco)).mp. 14 
3 e-cig$.mp. 1188 
4 Ecig$.mp. 59 
5 (Vape or vaping or vaper or vapers).mp. 252 
6 (Vapori#e$ adj3 (cigarette$ or nicotine)).mp. 33 
7 ((electric or electronic) adj2 (cig$ or nicotine or tobacco or smoking)).mp. 1215 
8 (e-sigaret$ or "e-sígarett$" or een sigaret$ or E-Zigarette$ or "cigarette$ 
électronique$" or "L'e-cigarette" or vapoteuse$ or "cigarrill$ electrónico$" or 
sigarett$ elettronic$ or sigarett$ elettronik$ or sigarett$ elettroniche$ or 
elektronik$ sigar$ or e-savuke$ or e-rokok$ or rokok$ elektronik$ or e-
papieros$ or e-ugwayi).mp. 
1 
9 (mods adj5 (tobacco or nicotine)).mp. 1 
10 Juul$.mp. 27 
11 (e-juice$ or e-liquid$).mp. 76 
12 (cig-a-like$ or cigalike$ or ciga-like$).mp. 21 
13 (e-hookah$ or electronic hookah$ or "hookah pens").mp. 6 
14 (ENNDS or electronic non-nicotine delivery).mp. 0 
15 ((NMNDS and nicotin$) or non-medicinal nicotine delivery system$).mp. 0 





17 (Heated tobacco product$ or tobacco heating product$ or tobacco heating 
system$).mp. 
6 
18 ("heat-not-burn" or "heat not burn" or "heat notburn" or "heatnot 
burn").mp. 
14 
19 (Heatsticks or heat-sticks or tobacco sticks or Neosticks).mp. 2 
20 ((HEETS or Fiit or glo) adj3 (tobacco or nicotine or smok$)).mp. 0 
21 (IQOS or iFuse or Ploom).mp. 6 
22 (electrically-heated smoking system and (nicotin$ or tobacco$)).mp. 0 
23 (Vapotage or "tabac chauffé" or "verhitte tabak" or "riscaldatori di tabacco" 
or "tabacco riscaldato" or "erhitzter Tabak" or "verhit tabak" or "zahřátý 
tabák" or "opvarmet tobak" or "oppvarmet tobakk" or "uppvärmd tobak" or 
"tabaco aquecido" or "kuumutatud tubakas" or "pinainit na tabako" or 





"apsildāmā tabaka" or "tembakau dipanaskan" or "šildomas tabakas" or 
"tembakau yang dipanaskan" or "te taakapa" or "podgrzewany tytoń" or 
"tabaco aquecido" or "încălzit tutunul" or "zahriaty tabak" or "ogrevani 
tobak" or "tabaco caliente" or "ısıtılmış tütün" or "ugwayi ovuthayo" or 
"thuốc lá nóng").mp. 







25 16 or 24 1518 
 
4. Elsevier Embase search strategy and results 
Elsevier Embase: E-cigarettes and HeatNotBurn devices 
Database Elsevier Embase 
Date of Search 15.04.2019 




Language limits None used in the search 
Date limits None, apart from the limits set by the invention of e-cigarettes (2003-4) and HeatNotBurn 
(approximately 1988 in their current forms) 
Study types Exclude animal models, cell lines 
Publication 
types 





Search terms Results 
E-cigarettes #1 'vaping'/exp OR 'vaping'  1,014 
#2 'electronic cigarette'/exp  4,468 
#3 'e cig*':ti,ab,kw  3,604 
#4 ecig*:ti,ab,kw  212 
#5 vape:ti,ab,kw OR vaping:ti,ab,kw OR vaper:ti,ab,kw OR vapers:ti,ab,kw    803 
#6 vapori?e$ NEAR/3 (cigarette* OR nicotine)  79 
#7  ((electric OR electronic) NEAR/2 (cig* OR nicotine OR tobacco OR 
smoking)):ti,ab,kw  
3,046 
#8 'e sigaret*':ti,ab,kw OR 'e sígarett*':ti,ab,kw OR 'e zigarette*':ti,ab,kw 
OR 'cigarette* électronique*':ti,ab,kw OR 'l e cigarette':ti,ab,kw OR 
vapoteuse*:ti,ab,kw OR 'cigarrill* electrónico*':ti,ab,kw OR 'sigarett* 
elettronic*':ti,ab,kw OR 'sigarett* elettronik*':ti,ab,kw OR 'sigarett* 
elettroniche*':ti,ab,kw OR 'elektronik* sigar*':ti,ab,kw OR 'e 
savuke*':ti,ab,kw OR 'e rokok*':ti,ab,kw OR 'rokok* 
elektronik*':ti,ab,kw OR 'e papieros*':ti,ab,kw OR 'e ugwayi':ti,ab,kw  
9 
#9  (mods NEAR/5 (tobacco OR nicotin* OR smoking OR 
cigarette)):ti,ab,kw  
2 
#10 'juul*':ti,ab,kw  42 




#12 'cig-a-like*':ti,ab,kw OR 'cigalike*':ti,ab,kw OR 'ciga-like*':ti,ab,kw OR 
'cig-alike':ti,ab,kw  
86 
#13 'e hookah*':ti,ab,kw OR 'electronic hookah*':ti,ab,kw OR 'electric 
hookah*':ti,ab,kw OR 'hookah pen*':ti,ab,kw OR 'e-shisha':ti,ab,kw OR 
'electronic shisha':ti,ab,kw OR 'electric shisha':ti,ab,kw  
17 
#14 'ennds':ti,ab,kw OR 'electronic non-nicotine delivery':ti,ab,kw  6 
#15 nmnds:ti,ab,kw AND nicotine:ti,ab,kw 0 
 #16 #1 OR #2 OR #3 OR #4 OR #5 OR #6 OR #7 OR #8 OR #9 OR #10 OR 




#17 'heated tobacco':ti,ab,kw OR 'tobacco heating':ti,ab,kw  183 
#18 'heat-not-burn':ti,ab,kw OR 'heat not burn':ti,ab,kw OR 'heat 
notburn':ti,ab,kw OR 'heatnot burn':ti,ab,kw  
104 
#19 'heatsticks':ti,ab,kw OR 'heatstick':ti,ab,kw OR 'heat-stick':ti,ab,kw OR 
'heat-sticks':ti,ab,kw OR 'tobacco sticks':ti,ab,kw OR 'tobacco 
stick':ti,ab,kw OR 'neostick':ti,ab,kw OR neosticks:ti,ab,kw  
17 
#20  ((heets OR fiit OR glo OR ifuse) NEAR/3 (tobacco OR nicotine OR 
smok*)):ti,ab,kw  
5 
#21 iqos:ti,ab,kw OR ploom:ti,ab,kw  55 
#22 'electrically-heated smoking system':ti,ab,kw AND (nicotin*:ti,ab,kw 
OR tobacco*:ti,ab,kw)  
1 
#23 vapotage:ti,ab,kw OR 'tabac chauffé':ti,ab,kw OR 'verhitte 
tabak':ti,ab,kw OR 'riscaldatori di tabacco':ti,ab,kw OR 'tabacco 
riscaldato':ti,ab,kw OR 'erhitzter tabak':ti,ab,kw OR 'verhit 
tabak':ti,ab,kw OR 'zahřátý tabák':ti,ab,kw OR 'opvarmet 
tobak':ti,ab,kw OR 'oppvarmet tobakk':ti,ab,kw OR 'uppvärmd 
tobak':ti,ab,kw OR 'kuumutatud tubakas':ti,ab,kw OR 'pinainit na 
tabako':ti,ab,kw OR 'lämmitetty tupakka':ti,ab,kw OR 'shan taba mai 
tsanani':ti,ab,kw OR 'hitað tóbak':ti,ab,kw OR 'apsildāmā 
tabaka':ti,ab,kw OR 'tembakau dipanaskan':ti,ab,kw OR 'šildomas 
tabakas':ti,ab,kw OR 'tembakau yang dipanaskan':ti,ab,kw OR 'te 
taakapa':ti,ab,kw OR 'podgrzewany tytoń':ti,ab,kw OR 'tabaco 
aquecido':ti,ab,kw OR 'încălzit tutunul':ti,ab,kw OR 'zahriaty 
tabak':ti,ab,kw OR 'ogrevani tobak':ti,ab,kw OR 'tabaco 
caliente':ti,ab,kw OR 'ısıtılmış tütün':ti,ab,kw OR 'ugwayi 
ovuthayo':ti,ab,kw OR 'thuốc lá nóng':ti,ab,kw  
1 





#25 #16 OR #24  5,850 
Animal, in 
vitro or cell 
line studies 
#26 'animal'/exp NOT 'human'/exp  5,227,7
28 
#27 'experimental animal'/exp  623,633 
#28 'animal experiment'/exp  2,359,9
62 
#29 'nonhuman'/exp  5,756,9
36 
#30 'animal model'/exp  1,244,8
03 





#32 'veterinary clinical trial'/exp  2 
#33 animal NEAR/2 (model* OR stud* OR experiment* OR laboratory)  2,716,1
11 
#34 cat:ti,ab,kw OR cats:ti,ab,kw OR feline:ti,ab,kw OR dog:ti,ab,kw OR 
dogs:ti,ab,kw OR canine:ti,ab,kw OR rat:ti,ab,kw OR rats:ti,ab,kw OR 
wistar:ti,ab,kw OR 'sprague dawley':ti,ab,kw OR rodent*:ti,ab,kw OR 
mouse:ti,ab,kw OR mice:ti,ab,kw OR murine:ti,ab,kw OR 
zebrafish:ti,ab,kw OR fish:ti,ab,kw OR chicken*:ti,ab,kw OR 
horse*:ti,ab,kw OR rabbit*:ti,ab,kw OR 'c. elegans':ti,ab,kw OR 
'caenorhabditis elegans':ti,ab,kw OR nematod*:ti,ab,kw OR 
xenopus:ti,ab,kw OR bird:ti,ab,kw OR birds:ti,ab,kw OR reptil*:ti,ab,kw 
OR livestock:ti,ab,kw OR larva*:ti,ab,kw  
4,327,8
95 
#35 'human tissue, cells or cell components'/exp  2,434,6
43 
#36 'bioassay'/exp  250,786 
#37 'in vitro study'/exp  5,605,0
74 
#38 'in vitro':ti,ab,kw OR 'biological assay*':ti,ab,kw OR 'cell 
culture':ti,ab,kw OR 'cultured cells':ti,ab,kw OR 'cell lines':ti,ab,kw OR 
'cell transformation assay*':ti,ab,kw  
1,769,3
94 
#39 #26 OR #27 OR #28 OR #29 OR #30 OR #31 OR #32 OR #33 OR #34 OR 








in vitro or 
Cell lines 





#41 'editorial'/exp  603,392 
 #42 'note'/exp  706,258 
#43  ('editorial'/it OR 'note'/it) AND ([editorial]/lim OR [note]/lim)  1,337,1
86 
#44 'reply':ti  77,815 
#45 commentary:ti  51,142 
#46 editorial:ti  72,014 
#47 note:ti  28,805 



















5. NHS NIHR PROSPERO  
NHS NIHR PROSPERO E-cigarettes and heat-not-burn products 
Database NHS NIHR PROSPERO https://www.crd.york.ac.uk/prospero/#searchadvanced 
Date of Search 15.04.2019 
Note “All status reviews, All fields” used 




Language limits None used in the search 
Date limits None, apart from the limits set by the invention of e-cigarettes (2003-4) and HeatNotBurn 
(approximately 1988 in their current forms) 







Search terms Search 
results 
E-cigarettes #1 e-cig* 62 
#2 ecig* 3 
#3 MeSH DESCRIPTOR Vaping EXPLODE ALL TREES 6 
#4 e-juic* 2 
#5 e-liquid* 4 
#6 cig-a-like OR cigalike OR cig-alike OR ciga-like 0 
#7 e-hookah 5 
#8 juul 26 
#9 vape 11 
#10 vaping 22 
#11 #1 OR #2 OR #3 OR #4 OR #5 OR #6 OR #7 OR #8 
OR #9 OR #10 
92 
HnB #12 "heated tobacco" OR "tobacco heating" 2 
#13 "heat-not-burn" OR "heat not burn" OR "heat 
notburn" OR "heatnot burn" 
2 
#14 heatsticks OR "heat-sticks" OR "tobacco sticks" 
OR neosticks 
0 
#15 iqos OR ploom OR iFuse 1 
#16 "electrically heated smoking system" AND 
tobacco 
0 
#17 #16 OR #15 OR #14 OR #13 OR #12 4 
E-cigarettes OR heat-not-
burn products 





6. LILACS (Latin American and Caribbean Health Sciences Literature) 
LILACS: E-cigarettes and heat-not-burn products devices 
Database LILACS (Including databases: (LILACS, IBECS, CUMED, BDENF – Nursing, BBO – Dentistry, 
WHO IRIS, PAHO-IRIS, Index Psychology - Scientific journals, MedCarib) 
Date of Search 15.04.2019 




Language limits None used in the search 
Date limits None, apart from the limits set by the invention of e-cigarettes (2003-4) and HeatNotBurn 
(approximately 1988 in their current forms) 
Study types Exclude animal models, cell lines 
Publication 
types 
Exclude commentary, editorials, replies. Letters are not outright excluded as research 
letters are in scope. 
Search number Search terms Search results 
1 (tw:(("E-cigarette" OR "E-cigarettes" OR “ecigarette” or 
“ecigarettes” OR vaping OR vape OR "electronic 
nicotine" OR "cig-a-like" OR "e-hookah" OR "E-liquid" OR 
"E-juice") )) 
 
2 “cigarrillo electrónico” OR “cigarrillo electrónico” OR OR 
“e-cigarros” OR “e-cigarro” OR "cigarette électronique" 
OR "cigarettes électroniques" OR “e-sigaretten” OR “een 
sigaret” OR “sigaretta elettronica” OR “sigarette 
elettroniche” 
 
3 "heated tobacco" OR "tobacco heating" OR "heat-not-
burn" OR "heat not burn" OR IQOS OR heatsticks OR 
"heat-sticks" OR "tobacco sticks" 
 
4 Vapotage OR "tabac chauffé" OR "verhitte tabak" OR 
"riscaldatori di tabacco" OR "tabacco riscaldato" OR 




Database results Show in 
graphical form:  
    total n=4061 
MEDLINE (4019) 
    IBECS (21) 
    LILACS (14) 
    DeCS - Descriptors in Health 
Sciences (2) 
    WHO IRIS (2) 
    BRISA/RedTESA (1) 
    LIS -Health Information 
Locator (1) 








7. Google scholar 
 
Google Scholar: E-cigarettes and heat-not-burn products 
Search Engine 
and Browser 
Google Scholar on Firefox 66 
Date of Search 15.04.2019 
Note Due to the simple search interface, reduced searches were used for the two research 
concepts. Limitation of using Google Scholar include limited search faceting and the 
unknown algorithm sorting the results.  




Language limits None used in the search 
Date limits None, apart from the limits set by the invention of e-cigarettes (2003-4) and heat-not-
burn products (approximately 1988 in their current forms) 





Concept Search terms Results Results considered 
E-cigarettes (E-cigarette OR ecigarette OR Vape OR 
Vaping OR Vaper OR e-juice OR e-liquid 
OR e-hookah) 
About 28,700 results 
(0.56 sec) 
First 100 results (first 




"heated tobacco" OR "tobacco heating" 
OR "heat-not-burn" OR "heat not burn" 
OR "IQOS" OR "heatsticks" OR "heat-
sticks" OR "tobacco sticks" 
About 4,140 results (0.34 
sec) 
First 100 results (first 




CORE.ac.uk E-cigarettes and heat-not-burn products 
Repository  CORE.ac.uk (The Open University and JISC) 
Date of Search 15.04.2019 
Note Due to the simple search interface, reduced searches were used. Search terms were 
limited to e-cigarette and vaping terms. 




Language limits None used in the search.  
Date limits None  
Study types None excluded in the search 
Publication 
types 
None excluded in the search 





ecigarette OR Vape OR 
Vaping OR Vaper)) 




OR "tobacco heating" OR 
"heated tobacco" OR 
"heat not burn" OR IQOS 
OR heatnotburn )  




9. List of reviews and reports used for citation searching in supplemental 
searches  
Reviews 
1. El Dib R, Suzumura EA, Akl EA, et al.77 Electronic nicotine delivery systems and/or electronic non-nicotine 
delivery systems for tobacco smoking cessation or reduction: A systematic review and meta-analysis. 
BMJ Open 2017;7(2):e012680. doi: 10.1136/bmjopen-2016-012680 [published Online First: 23 Feb 
2017] 
2. Evans SE, Hoffman AC.78 Electronic cigarettes: Abuse liability, topography and subjective effects. Tob Control 
2014;23 Suppl 2:ii23-9. doi: 10.1136/tobaccocontrol-2013-051489 [published Online First: 14 Apr 
2014] 
3. Glasser A, Abudayyeh H, Cantrell J, et al.25 Patterns of e-cigarette use among youth and young adults: Review 
of the impact of e-cigarettes on cigarette smoking. Nicotine Tob Res 2019;21(10):1320-30. doi: 
10.1093/ntr/nty103 [published Online First: 17 May 2018] 
4. Glasser AM, Collins L, Pearson JL, et al.79 Overview of electronic nicotine delivery systems: A systematic 
review. Am J Prev Med 2017;52(2):e33-e66. doi: 10.1016/j.amepre.2016.10.036 [published Online 
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Database Syst Rev 2016;9:Cd010216. doi: 10.1002/14651858.CD010216.pub3 [published Online First: 
13 Sep 2016] 
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9. Liu X, Lu W, Liao S, et al.84 Efficiency and adverse events of electronic cigarettes: A systematic review and 
meta-analysis (PRISMA-compliant article). Medicine (Baltimore) 2018;97(19):e0324. doi: 
10.1097/md.0000000000010324 [published Online First: 11 May 2018] 
10. Livingston CJ, Freeman RJ, Costales VC, et al.85 Electronic nicotine delivery systems or e-cigarettes: American 
College of Preventive Medicine's practice statement. Am J Prev Med 2019;56(1):167-78. doi: 
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11. Malas M, van der Tempel J, Schwartz R, et al.86 Electronic cigarettes for smoking cessation: A systematic 
review. Nicotine Tob Res 2016;18(10):1926-36. doi: 10.1093/ntr/ntw119 [published Online First: 25 
Apr 2016] 
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of e-cigarettes and vapour devices Victoria, Canada: Canadian Institute for Substance Use Research, 
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[published Online First: 30 Mar 2015] 
 
Reports 
1. Bals R, Boyd J, Esposito S, et al.89 Electronic cigarettes: A task force report from the European Respiratory 
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5. Wells C, Farrah K.93 Electronic cigarettes for the reduction or cessation of smoking: clinical utility, safety, and 
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Appendix 2: Quality assessment-tool and results 
1. Was the research question or objective in this paper clearly stated? 
2. Was the study population clearly specified and defined?  
3. Was the participation rate of eligible persons at least 50%? 
4. Were all the subjects selected or recruited from the same or similar populations (including the 
same time period)? Were inclusion and exclusion criteria for being in the study prespecified and 
applied uniformly to all participants?  
5. Was a sample size justification, power description, or variance and effect estimates provided?  
6. For the analyses in this paper, were the exposure(s) of interest measured prior to the outcome(s) 
being measured?  
7. Was the timeframe sufficient so that one could reasonably expect to see an association between 
exposure and outcome if it existed?  
8. For exposures that can vary in amount or level, did the study examine different levels of the 
exposure as related to the outcome (e.g., categories of exposure, or exposure measured as 
continuous variable)?  
9. Were the exposure measures (independent variables) clearly defined, valid, reliable, and 
implemented consistently across all study participants?  
10. Was the exposure(s) assessed more than once over time? 
11.  Were the outcome measures (dependent variables) clearly defined, valid, reliable, and 
implemented consistently across all study participants?  
12. Were the outcome assessors blinded to the exposure status of participants?  
13. Was loss to follow-up after baseline 20% or less?  
14. Were key potential confounding variables measured and adjusted statistically for their impact on 





Study ID QA1 QA2 QA3 QA4 QA5 QA6 QA7 QA8 QA9 QA10 QA11 QA12 QA13 QA14 
Aleyan 201853 Y Y Y Y NR Y Y N Y N Y N/A (self-report) N N/A 
Hammond 
201750 
Y Y Y Y 
N [Variance cannot 
be used as this is a 
convenience 
sample] 
Y Y N Y N Y N/A (self-report) N Partial 
Barrington-
Trimis 2018a35 
Y Y CD CD 
N [Variance cannot 




Y CD N Y Y Y N/A (self-report) N N 
Barrington-
Trimis 2018b36 
Y Y (no mean age) NR Y NR Y Y N Y N Y N/A (self-report) N N/a 
Barrington-
Trimis 201634 
Y Y Y N 
N [Justification for 
matched cases not 
provided - sample 
size restricted 
inappropriately] 
Y Y N Y 
Y (but not 
reported) 
Y N/a (self- report) N Partial 
Berry 201937 Y Y Y Y Y Y Y N Y 
Y (but not 
reported) 
Y N/A (self-report) Y Y 
Watkins 
201838 
Y Y Y Y Y Y Y Y Y N Y N/A (self-report) Y Y 
Conner 201839 Y Y CD Y 
N [Variance cannot 
be used as this is a 
sample of controls 
in an RCT] 
Y Y Y Y N Y N/A (self-report) N Y 
East 201840 Y Y N N - this was a non-
probability sample 
NR [Variance 
cannot be used as 




- quotas set by 
age gender, GOR 




Y Y? Y Y 
N [Variance cannot 
be used as this is a 
convenience 
sample] 
Y Y N Y Y Y N/A (self- report) Y Y 
Leventhal 
201652 
Y Y Y Y 
N [Variance cannot 
be used as this is a 
convenience 
sample] 
Y Y Y Y N Y N/A (self-report) Y Y 
Lozano 201741 Y Y Y Y Y Y Y N Y N Y N/A (self- report) N Y 
Miech 201751 Y Y Y Y Y Y Y N Y N Y N/A (self- report) N Partial 
Morgenstern 
201842 
Y Y y Y Y Y Y N Y N Y N/A (self- report) Y Partial 
Spindle 201743 Y Y Y Y Y Y Y N Y Y Y N/A (self- report) N Y 




CD Y Y Y Y Y 
Y [but not 
reported] 
Y N/A (self- report) N Partial 
Wills 201645 Y Y Y Y Y Y Y N Y 
Y [but not 
reported] 
Y N/A (self- report) N Y 
Wills 2017a46 Y Y Y Y Y Y Y N Y 
Y [but not 
reported] 
Y N/A (self- report) N Partial 
Wills 2017b47 Y Y Y Y Y Y Y Y Y Y Y N/A (self- report) N Partial 
Best 201848 Y Y Y Y Y Y Y Y Y N Y NA (self-report) N Y 
Kinnunen 
201949 




Appendix 3: Meta-analysis-feasibility  
Feasibility analysis 
1. Collapsed duplicates – 14 unique studies 
2. Separated studies by outcome and exposure 
a. Will look at ever smoked (outcome) and ever tried e-cigarette at baseline 
(exposure) as there is data to look at this 
b. Chose studies that report AOR  
c. Chose studies with longest follow up period 
d. Cannot look at past 30 day use of smoking as only Watkins/Spindle have complete 
data and have had to correct Table 2 in Spindle 201738 43  
3. Separated studies by length of follow up period 
a. Decided to include all time lengths as could not find evidence suggesting when 
effect should have taken place 
b. Will do subgroup analyses 
4. Cannot separate studies by e-cigarette type as information is not available 
a. Will do subgroup of pre/post 2014- as this is the point at which e-cigarette use 
rapidly increased in US. 
5. Separated studies by way measured 
a. Can calculate ORs for most  
b. Can only use those with AOR in main analyses (n=10) 
6. All together will use 9: Barrington-Trimis (2016), Berry (2019), Conner (2018), East (2018), 






Unadjusted meta-analysis: ever e-cigarette use 
 
Sensitivity: only 3-domain covariate adjusted studies retained 
 






Subgroup: pre/post 2014 
 
 













Meta-analysis: past 30 day e-cigarette use 
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